https://trial.medpath.com/news/nutraveri-launches-deterministic-ai-readiness-score-for-supplement-founders-replacing-black-box-models-with-auditable-regulatory-intelligence 2026-07-02T21:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutraveri-launches-deterministic-ai-readiness-score-for-supplement-founders-replacing-black-box-models-with-auditable-regulatory-intelligence 2026-07-02T21:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/sitting-for-more-than-30-minutes-at-a-time-linked-to-higher-cancer-death-risk-large-uk-biobank-study-finds 2026-07-02T21:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sitting-for-more-than-30-minutes-at-a-time-linked-to-higher-cancer-death-risk-large-uk-biobank-study-finds 2026-07-02T21:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/usc-scientists-target-cpla2-enzyme-to-halt-brain-inflammation-in-apoe4-carriers-backed-by-3-million-pattiz-foundation-gift 2026-07-02T21:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usc-scientists-target-cpla2-enzyme-to-halt-brain-inflammation-in-apoe4-carriers-backed-by-3-million-pattiz-foundation-gift 2026-07-02T21:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/vamorolone-demonstrates-glucocorticoid-activity-without-clinically-meaningful-immunosuppression-in-phase-i-study 2026-07-02T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vamorolone-demonstrates-glucocorticoid-activity-without-clinically-meaningful-immunosuppression-in-phase-i-study 2026-07-02T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/eight-hour-eating-window-sustains-long-term-weight-loss-one-year-follow-up-study-shows 2026-07-02T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-hour-eating-window-sustains-long-term-weight-loss-one-year-follow-up-study-shows 2026-07-02T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/ucl-and-eisai-extend-neurodegenerative-disease-drug-discovery-partnership-through-2030 2026-07-02T20:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucl-and-eisai-extend-neurodegenerative-disease-drug-discovery-partnership-through-2030 2026-07-02T20:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/h5n1-bird-flu-detected-in-new-zealand-for-the-first-time-as-australia-braces-for-poultry-impact 2026-07-02T20:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/h5n1-bird-flu-detected-in-new-zealand-for-the-first-time-as-australia-braces-for-poultry-impact 2026-07-02T20:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/from-infectious-devastation-to-chronic-disease-how-250-years-of-american-medicine-transformed-mortality 2026-07-02T20:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-infectious-devastation-to-chronic-disease-how-250-years-of-american-medicine-transformed-mortality 2026-07-02T20:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-guided-drug-combinations-may-overcome-treatment-resistance-in-advanced-melanoma 2026-07-02T19:10:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-guided-drug-combinations-may-overcome-treatment-resistance-in-advanced-melanoma 2026-07-02T19:10:41+00:00 hourly 0.9 https://trial.medpath.com/news/macrophage-like-cells-emerge-as-dynamic-biomarker-for-tracking-diabetic-macular-edema-treatment-response 2026-07-02T19:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macrophage-like-cells-emerge-as-dynamic-biomarker-for-tracking-diabetic-macular-edema-treatment-response 2026-07-02T19:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/resorantel-a-dual-targeting-therapeutic-with-potent-efficacy-against-staphylococcus-aureus 2026-07-02T19:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resorantel-a-dual-targeting-therapeutic-with-potent-efficacy-against-staphylococcus-aureus 2026-07-02T19:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/india-amends-drugs-rules-to-bring-cell-and-gene-therapies-under-centralized-regulatory-oversight 2026-07-02T19:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-amends-drugs-rules-to-bring-cell-and-gene-therapies-under-centralized-regulatory-oversight 2026-07-02T19:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/major-investment-launches-precision-health-platform-in-western-sweden-to-accelerate-personalised-medicine 2026-07-02T19:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-investment-launches-precision-health-platform-in-western-sweden-to-accelerate-personalised-medicine 2026-07-02T19:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-car-t-therapy-gcar1-shows-early-promise-against-treatment-resistant-solid-tumors 2026-07-02T19:10:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-car-t-therapy-gcar1-shows-early-promise-against-treatment-resistant-solid-tumors 2026-07-02T19:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-markers-spop-and-chd1-identified-as-key-determinants-of-ferroptosis-sensitivity-in-advanced-prostate-cancer 2026-07-02T19:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-markers-spop-and-chd1-identified-as-key-determinants-of-ferroptosis-sensitivity-in-advanced-prostate-cancer 2026-07-02T19:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/gea-invests-eur4-million-in-sarstedt-biotechnology-center-to-bridge-lab-to-industrial-scale-up-gap 2026-07-02T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gea-invests-eur4-million-in-sarstedt-biotechnology-center-to-bridge-lab-to-industrial-scale-up-gap 2026-07-02T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/cannabix-technologies-expands-breath-based-drug-testing-platform-to-detect-methamphetamine-and-amphetamine 2026-07-02T19:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabix-technologies-expands-breath-based-drug-testing-platform-to-detect-methamphetamine-and-amphetamine 2026-07-02T19:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/explainable-ai-model-predicts-immunotherapy-outcomes-in-metastatic-renal-cell-carcinoma-the-meet-uro-15-ai-study 2026-07-02T19:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/explainable-ai-model-predicts-immunotherapy-outcomes-in-metastatic-renal-cell-carcinoma-the-meet-uro-15-ai-study 2026-07-02T19:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/umass-memorial-nurses-overwhelmingly-authorize-14-day-strike-amid-staffing-and-safety-concerns 2026-07-02T19:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/umass-memorial-nurses-overwhelmingly-authorize-14-day-strike-amid-staffing-and-safety-concerns 2026-07-02T19:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-340b-payment-cuts-and-site-neutral-imaging-payments-in-2027-opps-rule 2026-07-02T18:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-proposes-340b-payment-cuts-and-site-neutral-imaging-payments-in-2027-opps-rule 2026-07-02T18:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/spinogenix-appoints-harvard-neuroscience-leaders-to-scientific-advisory-board-as-synaptic-regenerative-therapy-advances 2026-07-02T18:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spinogenix-appoints-harvard-neuroscience-leaders-to-scientific-advisory-board-as-synaptic-regenerative-therapy-advances 2026-07-02T18:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/patient-engagement-emerges-as-the-rate-limiting-step-in-clinical-trial-participation 2026-07-02T18:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-engagement-emerges-as-the-rate-limiting-step-in-clinical-trial-participation 2026-07-02T18:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-s-new-neurological-assessment-center-to-transform-routine-data-capture-into-clinical-research-goldmine 2026-07-02T18:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-s-new-neurological-assessment-center-to-transform-routine-data-capture-into-clinical-research-goldmine 2026-07-02T18:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/three-health-systems-compete-for-225-acute-care-beds-in-new-hanover-county-north-carolina 2026-07-02T17:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-health-systems-compete-for-225-acute-care-beds-in-new-hanover-county-north-carolina 2026-07-02T17:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/retinal-vasculitis-signals-emerge-across-intravitreal-anti-vegf-and-complement-inhibitor-therapies 2026-07-02T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retinal-vasculitis-signals-emerge-across-intravitreal-anti-vegf-and-complement-inhibitor-therapies 2026-07-02T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/arima-genomics-partners-with-active-motif-to-distribute-hi-c-research-kits-sharpening-focus-on-clinical-cancer-diagnostics 2026-07-02T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arima-genomics-partners-with-active-motif-to-distribute-hi-c-research-kits-sharpening-focus-on-clinical-cancer-diagnostics 2026-07-02T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-cspc-pharma-expand-partnership-with-1-77-billion-sirna-deal-for-kidney-diseases 2026-07-02T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-cspc-pharma-expand-partnership-with-1-77-billion-sirna-deal-for-kidney-diseases 2026-07-02T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-briefing-documents-cast-doubt-on-capricor-s-deramiocel-for-duchenne-muscular-dystrophy-shares-plunge-60 2026-07-02T16:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-briefing-documents-cast-doubt-on-capricor-s-deramiocel-for-duchenne-muscular-dystrophy-shares-plunge-60 2026-07-02T16:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/r-opra-launches-full-cycle-production-of-abbvie-s-paricalcitol-generic-dekalpar-for-chronic-kidney-disease-in-moscow 2026-07-02T16:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r-opra-launches-full-cycle-production-of-abbvie-s-paricalcitol-generic-dekalpar-for-chronic-kidney-disease-in-moscow 2026-07-02T16:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/culture-media-and-trust-shape-gmo-acceptance-in-nigeria-study-finds 2026-07-02T16:10:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/culture-media-and-trust-shape-gmo-acceptance-in-nigeria-study-finds 2026-07-02T16:10:41+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-sinusitis-inflammation-remains-difficult-to-control-despite-targeted-therapies 2026-07-02T16:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chronic-sinusitis-inflammation-remains-difficult-to-control-despite-targeted-therapies 2026-07-02T16:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/ema-launches-comprehensive-initiative-to-address-gender-gap-in-medicines-development-for-women-s-health 2026-07-02T16:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-launches-comprehensive-initiative-to-address-gender-gap-in-medicines-development-for-women-s-health 2026-07-02T16:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/chicago-area-health-systems-race-to-expand-cancer-care-infrastructure-amid-rising-demand 2026-07-02T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chicago-area-health-systems-race-to-expand-cancer-care-infrastructure-amid-rising-demand 2026-07-02T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/kenya-launches-five-year-local-manufacturing-strategy-to-reduce-pharmaceutical-import-dependence 2026-07-02T16:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kenya-launches-five-year-local-manufacturing-strategy-to-reduce-pharmaceutical-import-dependence 2026-07-02T16:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/nih-unveils-world-s-largest-genomics-and-health-database-linking-535000-whole-genomes-to-medical-records 2026-07-02T14:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-unveils-world-s-largest-genomics-and-health-database-linking-535000-whole-genomes-to-medical-records 2026-07-02T14:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-launches-ai-focused-postdoctoral-fellowships-in-digital-pathology-and-chemical-synthesis-prediction 2026-07-02T14:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-launches-ai-focused-postdoctoral-fellowships-in-digital-pathology-and-chemical-synthesis-prediction 2026-07-02T14:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/besins-healthcare-acquires-unid-manufacturing-to-bolster-long-acting-drug-delivery-capabilities 2026-07-02T14:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/besins-healthcare-acquires-unid-manufacturing-to-bolster-long-acting-drug-delivery-capabilities 2026-07-02T14:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/advicenne-withdraws-adv7103-new-drug-application-in-the-usa-for-distal-renal-tubular-acidosis 2026-07-02T14:10:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advicenne-withdraws-adv7103-new-drug-application-in-the-usa-for-distal-renal-tubular-acidosis 2026-07-02T14:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-advances-phase-3-trial-of-trastuzumab-rezetecan-in-platinum-resistant-ovarian-cancer-following-dcgi-approval 2026-07-02T14:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-advances-phase-3-trial-of-trastuzumab-rezetecan-in-platinum-resistant-ovarian-cancer-following-dcgi-approval 2026-07-02T14:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-call-for-urgent-integration-of-female-genital-schistosomiasis-screening-into-hiv-and-cervical-cancer-programmes 2026-07-02T14:10:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-call-for-urgent-integration-of-female-genital-schistosomiasis-screening-into-hiv-and-cervical-cancer-programmes 2026-07-02T14:10:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-infant-formula-adverse-event-reporting-gap-exposed-as-nec-lawsuits-mount-against-abbott-and-mead-johnson 2026-07-02T14:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-infant-formula-adverse-event-reporting-gap-exposed-as-nec-lawsuits-mount-against-abbott-and-mead-johnson 2026-07-02T14:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/japan-s-non-partisan-diet-members-briefed-on-hearing-loss-policy-challenges-and-regional-cancer-care-disparities 2026-07-02T14:10:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-s-non-partisan-diet-members-briefed-on-hearing-loss-policy-challenges-and-regional-cancer-care-disparities 2026-07-02T14:10:01+00:00 hourly 0.9 https://trial.medpath.com/news/celea-therapeutics-secures-180-million-to-launch-first-head-to-head-phase-3-trial-of-deupirfenidone-in-ipf 2026-07-02T14:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celea-therapeutics-secures-180-million-to-launch-first-head-to-head-phase-3-trial-of-deupirfenidone-in-ipf 2026-07-02T14:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/medically-tailored-meals-outperform-food-subsidies-in-lowering-hba1c-for-type-2-diabetes 2026-07-02T13:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medically-tailored-meals-outperform-food-subsidies-in-lowering-hba1c-for-type-2-diabetes 2026-07-02T13:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/inocras-and-aimedbio-partner-to-integrate-whole-genome-intelligence-into-adc-clinical-trials 2026-07-02T13:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inocras-and-aimedbio-partner-to-integrate-whole-genome-intelligence-into-adc-clinical-trials 2026-07-02T13:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-acquires-memo-therapeutics-in-deal-worth-up-to-eur700-million-validating-antibody-discovery-platform 2026-07-02T13:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-acquires-memo-therapeutics-in-deal-worth-up-to-eur700-million-validating-antibody-discovery-platform 2026-07-02T13:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/kku-to-host-12th-allied-health-sciences-international-symposium-2027-advancing-ai-and-precision-medicine-in-health-education 2026-07-02T13:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kku-to-host-12th-allied-health-sciences-international-symposium-2027-advancing-ai-and-precision-medicine-in-health-education 2026-07-02T13:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-talc-asbestos-testing-rule-withdrawal-exposes-deep-rift-between-maha-agenda-and-white-house-corporate-interests 2026-07-02T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-talc-asbestos-testing-rule-withdrawal-exposes-deep-rift-between-maha-agenda-and-white-house-corporate-interests 2026-07-02T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/easterseals-nh-breaks-ground-on-phase-ii-of-military-veterans-campus-in-franklin 2026-07-02T12:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/easterseals-nh-breaks-ground-on-phase-ii-of-military-veterans-campus-in-franklin 2026-07-02T12:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-s-envlo-becomes-first-korean-sglt-2-inhibitor-to-enter-mena-market-in-w145-2-billion-deal 2026-07-02T09:05:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daewoong-s-envlo-becomes-first-korean-sglt-2-inhibitor-to-enter-mena-market-in-w145-2-billion-deal 2026-07-02T09:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/michigan-cyclosporiasis-outbreak-surges-past-225-cases-as-health-officials-race-to-identify-source 2026-07-02T08:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/michigan-cyclosporiasis-outbreak-surges-past-225-cases-as-health-officials-race-to-identify-source 2026-07-02T08:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-markers-for-adhd-influence-toddler-activity-levels-landmark-study-of-80000-infants-reveals 2026-07-02T08:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-markers-for-adhd-influence-toddler-activity-levels-landmark-study-of-80000-infants-reveals 2026-07-02T08:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/peptide-ligand-discovery-for-gpcrs-a-comprehensive-primer-on-methods-tools-and-therapeutic-opportunities 2026-07-02T08:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptide-ligand-discovery-for-gpcrs-a-comprehensive-primer-on-methods-tools-and-therapeutic-opportunities 2026-07-02T08:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/asbmb-announces-new-committee-members-and-leadership-transitions-for-2025-2026-term 2026-07-02T06:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asbmb-announces-new-committee-members-and-leadership-transitions-for-2025-2026-term 2026-07-02T06:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-s-david-hung-on-building-a-pipeline-of-best-in-class-oncology-drugs 2026-07-02T06:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvation-bio-s-david-hung-on-building-a-pipeline-of-best-in-class-oncology-drugs 2026-07-02T06:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/global-trust-in-science-remains-high-despite-political-polarization-landmark-68-country-survey-reveals 2026-07-02T06:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-trust-in-science-remains-high-despite-political-polarization-landmark-68-country-survey-reveals 2026-07-02T06:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-blocks-colorado-s-first-in-nation-price-cap-on-amgen-s-arthritis-drug-enbrel 2026-07-02T06:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-judge-blocks-colorado-s-first-in-nation-price-cap-on-amgen-s-arthritis-drug-enbrel 2026-07-02T06:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/helix-launches-genosphere-mcp-connector-in-claude-to-accelerate-clinico-genomic-research 2026-07-02T05:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helix-launches-genosphere-mcp-connector-in-claude-to-accelerate-clinico-genomic-research 2026-07-02T05:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/first-synthetic-cell-built-from-scratch-achieves-growth-dna-replication-and-division 2026-07-02T05:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-synthetic-cell-built-from-scratch-achieves-growth-dna-replication-and-division 2026-07-02T05:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/reversing-macrophage-metabolism-may-improve-cancer-immunotherapy-outcomes 2026-07-02T04:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reversing-macrophage-metabolism-may-improve-cancer-immunotherapy-outcomes 2026-07-02T04:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/florida-becomes-first-state-to-mandate-ekg-screening-for-high-school-athletes-sparking-debate-over-benefits-and-harms 2026-07-02T04:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-becomes-first-state-to-mandate-ekg-screening-for-high-school-athletes-sparking-debate-over-benefits-and-harms 2026-07-02T04:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/junshi-biosciences-licenses-anti-il-17a-antibody-roconkibart-to-fosun-wanbang-in-greater-china-deal-worth-up-to-rmb-215-million-upfront 2026-07-02T02:15:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/junshi-biosciences-licenses-anti-il-17a-antibody-roconkibart-to-fosun-wanbang-in-greater-china-deal-worth-up-to-rmb-215-million-upfront 2026-07-02T02:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-drugs-market-projected-to-reach-13-3-billion-by-2033-driven-by-chronic-disease-burden-and-delivery-technology-innovation 2026-07-02T02:12:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-drugs-market-projected-to-reach-13-3-billion-by-2033-driven-by-chronic-disease-burden-and-delivery-technology-innovation 2026-07-02T02:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/the-contested-disease-how-obesity-classification-shapes-medicine-markets-and-patient-identity 2026-07-02T02:12:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-contested-disease-how-obesity-classification-shapes-medicine-markets-and-patient-identity 2026-07-02T02:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/seoul-st-mary-s-hospital-reaches-200-case-milestone-in-alzheimer-s-antibody-therapy 2026-07-02T02:12:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seoul-st-mary-s-hospital-reaches-200-case-milestone-in-alzheimer-s-antibody-therapy 2026-07-02T02:12:09+00:00 hourly 0.9 https://trial.medpath.com/news/leukaemia-uk-opens-final-project-grant-round-before-2027-pause-offering-up-to-ps250000-for-translational-blood-cancer-research 2026-07-02T01:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leukaemia-uk-opens-final-project-grant-round-before-2027-pause-offering-up-to-ps250000-for-translational-blood-cancer-research 2026-07-02T01:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/nona-biosciences-and-lonza-forge-strategic-collaboration-to-develop-single-domain-antibody-bbb-crossing-technology-for-cns-diseases 2026-07-02T01:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nona-biosciences-and-lonza-forge-strategic-collaboration-to-develop-single-domain-antibody-bbb-crossing-technology-for-cns-diseases 2026-07-02T01:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/treatments-have-leveled-cholesterol-and-blood-pressure-in-adults-over-40-with-obesity-landmark-lancet-study-finds 2026-07-02T01:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treatments-have-leveled-cholesterol-and-blood-pressure-in-adults-over-40-with-obesity-landmark-lancet-study-finds 2026-07-02T01:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/new-ats-cap-guidance-sparks-first-idsa-split-in-two-decades-over-empiric-antibiotics-in-viral-pneumonia 2026-07-01T22:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-ats-cap-guidance-sparks-first-idsa-split-in-two-decades-over-empiric-antibiotics-in-viral-pneumonia 2026-07-01T22:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-may-predict-which-colorectal-cancer-patients-benefit-from-adjuvant-chemotherapy-after-liver-metastasis-surgery 2026-07-01T22:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-may-predict-which-colorectal-cancer-patients-benefit-from-adjuvant-chemotherapy-after-liver-metastasis-surgery 2026-07-01T22:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/fondazione-telethon-to-lead-eur30-million-erdera-call-for-rare-disease-clinical-trials 2026-07-01T22:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fondazione-telethon-to-lead-eur30-million-erdera-call-for-rare-disease-clinical-trials 2026-07-01T22:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/heat-wave-warning-common-medications-that-increase-risk-of-heat-related-illness 2026-07-01T21:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heat-wave-warning-common-medications-that-increase-risk-of-heat-related-illness 2026-07-01T21:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/csf-turnover-dysfunction-identified-as-hidden-early-biomarker-in-irbd-offering-new-window-for-parkinson-s-intervention 2026-07-01T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csf-turnover-dysfunction-identified-as-hidden-early-biomarker-in-irbd-offering-new-window-for-parkinson-s-intervention 2026-07-01T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/aahrpp-awards-full-accreditation-to-merck-medstar-health-and-three-other-research-entities 2026-07-01T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aahrpp-awards-full-accreditation-to-merck-medstar-health-and-three-other-research-entities 2026-07-01T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/ai-analysis-reveals-over-250000-cancer-research-papers-show-signs-of-paper-mill-fabrication 2026-07-01T20:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-analysis-reveals-over-250000-cancer-research-papers-show-signs-of-paper-mill-fabrication 2026-07-01T20:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/trop2-identified-as-achilles-heel-of-aggressive-metastatic-colorectal-cancer-paving-way-for-adc-combination-therapy 2026-07-01T20:12:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trop2-identified-as-achilles-heel-of-aggressive-metastatic-colorectal-cancer-paving-way-for-adc-combination-therapy 2026-07-01T20:12:17+00:00 hourly 0.9 https://trial.medpath.com/news/melatonin-shows-comparable-efficacy-to-opioids-and-nsaids-for-chronic-musculoskeletal-pain-large-meta-analysis-finds 2026-07-01T20:11:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/melatonin-shows-comparable-efficacy-to-opioids-and-nsaids-for-chronic-musculoskeletal-pain-large-meta-analysis-finds 2026-07-01T20:11:13+00:00 hourly 0.9 https://trial.medpath.com/news/aob-pharma-partners-with-biorasi-to-accelerate-phase-2b-trial-of-b244-in-moderate-to-severe-acne 2026-07-01T20:11:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aob-pharma-partners-with-biorasi-to-accelerate-phase-2b-trial-of-b244-in-moderate-to-severe-acne 2026-07-01T20:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-alone-achieves-complete-response-in-mismatch-repair-deficient-gastroesophageal-junction-cancer-sparing-patient-from-chemotherapy-and-surgery 2026-07-01T20:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-alone-achieves-complete-response-in-mismatch-repair-deficient-gastroesophageal-junction-cancer-sparing-patient-from-chemotherapy-and-surgery 2026-07-01T20:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/eighth-circuit-denies-novartis-injunction-upholds-missouri-law-mandating-unlimited-340b-contract-pharmacy-access 2026-07-01T20:10:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eighth-circuit-denies-novartis-injunction-upholds-missouri-law-mandating-unlimited-340b-contract-pharmacy-access 2026-07-01T20:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-attracts-heavy-call-option-activity-as-market-bets-on-biotech-upside 2026-07-01T19:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-attracts-heavy-call-option-activity-as-market-bets-on-biotech-upside 2026-07-01T19:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/atrx-mutations-reshape-chromatin-architecture-to-drive-glioma-progression-exposing-hoxa-as-a-therapeutic-target 2026-07-01T19:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atrx-mutations-reshape-chromatin-architecture-to-drive-glioma-progression-exposing-hoxa-as-a-therapeutic-target 2026-07-01T19:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/biallelic-ehmt2-variants-identified-in-second-ever-case-of-autosomal-recessive-kleefstra-like-neurodevelopmental-syndrome 2026-07-01T18:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biallelic-ehmt2-variants-identified-in-second-ever-case-of-autosomal-recessive-kleefstra-like-neurodevelopmental-syndrome 2026-07-01T18:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/92bio-doses-first-patient-in-phase-1-trial-of-ntb-928-a-next-generation-bispecific-t-cell-engager-for-platinum-resistant-ovarian-cancer 2026-07-01T18:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/92bio-doses-first-patient-in-phase-1-trial-of-ntb-928-a-next-generation-bispecific-t-cell-engager-for-platinum-resistant-ovarian-cancer 2026-07-01T18:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/duke-heart-specialists-patel-and-shah-named-to-top-aha-volunteer-leadership-posts-for-2026-27 2026-07-01T18:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-heart-specialists-patel-and-shah-named-to-top-aha-volunteer-leadership-posts-for-2026-27 2026-07-01T18:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-and-chemical-features-unlock-mycomembrane-permeation-in-mycobacterium-tuberculosis 2026-07-01T18:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-and-chemical-features-unlock-mycomembrane-permeation-in-mycobacterium-tuberculosis 2026-07-01T18:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/unitedhealthcare-announces-august-2026-policy-updates-new-genetic-testing-prior-authorization-dme-process-changes-and-state-level-medicaid-reforms 2026-07-01T18:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unitedhealthcare-announces-august-2026-policy-updates-new-genetic-testing-prior-authorization-dme-process-changes-and-state-level-medicaid-reforms 2026-07-01T18:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-researchers-uncover-structural-basis-of-congenital-myasthenic-syndromes-paving-way-for-precision-therapies 2026-07-01T17:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-researchers-uncover-structural-basis-of-congenital-myasthenic-syndromes-paving-way-for-precision-therapies 2026-07-01T17:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/oregon-psilocybin-program-raises-safety-concerns-as-use-expands-beyond-medical-indications-johns-hopkins-study-finds 2026-07-01T17:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oregon-psilocybin-program-raises-safety-concerns-as-use-expands-beyond-medical-indications-johns-hopkins-study-finds 2026-07-01T17:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/lef1-identified-as-master-regulator-of-stem-t-cells-opening-new-therapeutic-avenues-across-chronic-diseases 2026-07-01T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lef1-identified-as-master-regulator-of-stem-t-cells-opening-new-therapeutic-avenues-across-chronic-diseases 2026-07-01T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-solaris-trial-subcutaneous-olanzapine-lai-demonstrates-efficacy-without-pdss-in-schizophrenia 2026-07-01T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-solaris-trial-subcutaneous-olanzapine-lai-demonstrates-efficacy-without-pdss-in-schizophrenia 2026-07-01T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/oral-shigella-vaccine-candidate-wrss2-demonstrates-89-efficacy-in-phase-2-controlled-human-infection-trial 2026-07-01T17:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-shigella-vaccine-candidate-wrss2-demonstrates-89-efficacy-in-phase-2-controlled-human-infection-trial 2026-07-01T17:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-device-authorizations-rise-in-h1-2026-but-approval-timelines-lengthen-significantly 2026-07-01T17:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-device-authorizations-rise-in-h1-2026-but-approval-timelines-lengthen-significantly 2026-07-01T17:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-secures-ema-approval-for-pediatric-expansion-of-rare-disease-drug-namuscla-in-non-dystrophic-myotonia 2026-07-01T16:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-secures-ema-approval-for-pediatric-expansion-of-rare-disease-drug-namuscla-in-non-dystrophic-myotonia 2026-07-01T16:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-mannkind-s-furoscix-readyflow-the-first-autoinjector-for-iv-equivalent-diuretic-therapy-in-heart-failure-and-ckd 2026-07-01T16:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-mannkind-s-furoscix-readyflow-the-first-autoinjector-for-iv-equivalent-diuretic-therapy-in-heart-failure-and-ckd 2026-07-01T16:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/polaritybio-submits-bla-for-skinte-a-first-in-class-autologous-therapy-for-diabetic-foot-ulcers 2026-07-01T16:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polaritybio-submits-bla-for-skinte-a-first-in-class-autologous-therapy-for-diabetic-foot-ulcers 2026-07-01T16:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-circular-rna-biomarkers-outperform-ptau217-in-early-alzheimer-s-detection-landmark-nature-medicine-study-shows 2026-07-01T15:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-based-circular-rna-biomarkers-outperform-ptau217-in-early-alzheimer-s-detection-landmark-nature-medicine-study-shows 2026-07-01T15:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-hif2-as-key-driver-of-coronary-damage-in-kawasaki-disease-opening-new-therapeutic-avenues 2026-07-01T14:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-hif2-as-key-driver-of-coronary-damage-in-kawasaki-disease-opening-new-therapeutic-avenues 2026-07-01T14:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/uta-launches-disease-anchored-ph-d-program-to-accelerate-rare-disease-research-and-treatment 2026-07-01T14:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uta-launches-disease-anchored-ph-d-program-to-accelerate-rare-disease-research-and-treatment 2026-07-01T14:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-ranks-ninth-in-gartner-s-2026-global-supply-chain-top-25-showcasing-ai-driven-resilience 2026-07-01T14:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-ranks-ninth-in-gartner-s-2026-global-supply-chain-top-25-showcasing-ai-driven-resilience 2026-07-01T14:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-pharmaceuticals-appoints-board-member-alison-l-hannah-m-d-as-chief-medical-officer-to-drive-oncology-pipeline 2026-07-01T14:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-pharmaceuticals-appoints-board-member-alison-l-hannah-m-d-as-chief-medical-officer-to-drive-oncology-pipeline 2026-07-01T14:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/medical-commercial-alignment-in-rare-disease-launches-fails-long-before-launch-day-experts-warn 2026-07-01T14:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-commercial-alignment-in-rare-disease-launches-fails-long-before-launch-day-experts-warn 2026-07-01T14:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/mankind-pharma-partners-with-denovo-sciences-to-launch-ai-driven-drug-discovery-program 2026-07-01T14:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mankind-pharma-partners-with-denovo-sciences-to-launch-ai-driven-drug-discovery-program 2026-07-01T14:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/mepolizumab-demonstrates-disease-stability-benefits-across-copd-severity-spectrum-at-ats-2026 2026-07-01T14:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mepolizumab-demonstrates-disease-stability-benefits-across-copd-severity-spectrum-at-ats-2026 2026-07-01T14:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/from-ions-to-immunotherapy-how-a-st-jude-scientist-is-designing-a-car-t-cell-trial-for-pediatric-brain-tumors 2026-07-01T13:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-ions-to-immunotherapy-how-a-st-jude-scientist-is-designing-a-car-t-cell-trial-for-pediatric-brain-tumors 2026-07-01T13:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-data-driven-approaches-poised-to-bridge-the-gap-between-cardiovascular-modeling-and-clinical-practice 2026-07-01T12:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-data-driven-approaches-poised-to-bridge-the-gap-between-cardiovascular-modeling-and-clinical-practice 2026-07-01T12:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-to-galderma-for-relabotulinumtoxina-over-manufacturing-observations 2026-07-01T12:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-to-galderma-for-relabotulinumtoxina-over-manufacturing-observations 2026-07-01T12:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-crack-mix-and-match-code-behind-bacterial-anti-cancer-drug-assembly-opening-door-to-engineered-hdac-inhibitors 2026-07-01T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-crack-mix-and-match-code-behind-bacterial-anti-cancer-drug-assembly-opening-door-to-engineered-hdac-inhibitors 2026-07-01T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/virtual-sustained-counseling-plus-nrt-nearly-doubles-smoking-quit-rates-in-cancer-patients-ecog-acrin-trial 2026-07-01T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virtual-sustained-counseling-plus-nrt-nearly-doubles-smoking-quit-rates-in-cancer-patients-ecog-acrin-trial 2026-07-01T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/valerio-therapeutics-to-acquire-etherna-immunotherapies-in-eur30m-deal-creating-fully-integrated-rna-medicines-company 2026-07-01T11:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valerio-therapeutics-to-acquire-etherna-immunotherapies-in-eur30m-deal-creating-fully-integrated-rna-medicines-company 2026-07-01T11:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/former-nfl-running-back-chris-johnson-reveals-als-diagnosis-deion-sanders-declares-himself-cancer-free 2026-07-01T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-nfl-running-back-chris-johnson-reveals-als-diagnosis-deion-sanders-declares-himself-cancer-free 2026-07-01T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/silk-based-bone-marrow-factories-move-lab-grown-platelets-closer-to-clinical-use 2026-07-01T10:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silk-based-bone-marrow-factories-move-lab-grown-platelets-closer-to-clinical-use 2026-07-01T10:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/skylinedx-s-merlin-cp-gep-earns-fda-breakthrough-device-designation-for-early-stage-melanoma-risk-assessment 2026-07-01T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skylinedx-s-merlin-cp-gep-earns-fda-breakthrough-device-designation-for-early-stage-melanoma-risk-assessment 2026-07-01T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/telum-therapeutics-secures-eur18-million-series-a-to-advance-novel-antimicrobial-against-acinetobacter-baumannii 2026-07-01T08:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telum-therapeutics-secures-eur18-million-series-a-to-advance-novel-antimicrobial-against-acinetobacter-baumannii 2026-07-01T08:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-harrington-rare-disease-centre-appoints-first-little-princess-trust-professor-of-paediatric-oncology-to-accelerate-rare-childhood-cancer-drug-discovery 2026-07-01T08:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-harrington-rare-disease-centre-appoints-first-little-princess-trust-professor-of-paediatric-oncology-to-accelerate-rare-childhood-cancer-drug-discovery 2026-07-01T08:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/ada-leads-coalition-opposing-proposed-rule-threatening-federal-diabetes-research-funding-as-143000-comments-filed 2026-07-01T08:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ada-leads-coalition-opposing-proposed-rule-threatening-federal-diabetes-research-funding-as-143000-comments-filed 2026-07-01T08:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-ai-for-missing-modality-learning-and-uncertainty-aware-medical-image-analysis-bridging-the-gap-between-idealized-ai-and-clinical-reality 2026-07-01T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-ai-for-missing-modality-learning-and-uncertainty-aware-medical-image-analysis-bridging-the-gap-between-idealized-ai-and-clinical-reality 2026-07-01T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/vaderis-launches-global-phase-3-heroic-trial-of-engasertib-for-hereditary-hemorrhagic-telangiectasia 2026-07-01T06:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaderis-launches-global-phase-3-heroic-trial-of-engasertib-for-hereditary-hemorrhagic-telangiectasia 2026-07-01T06:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/poland-expands-hcv-treatment-to-children-as-real-world-data-confirm-high-daa-efficacy-in-pediatric-patients 2026-07-01T06:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poland-expands-hcv-treatment-to-children-as-real-world-data-confirm-high-daa-efficacy-in-pediatric-patients 2026-07-01T06:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/telangana-bets-big-on-drug-discovery-hyderabad-poised-to-become-global-hub-for-next-generation-therapies 2026-07-01T06:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telangana-bets-big-on-drug-discovery-hyderabad-poised-to-become-global-hub-for-next-generation-therapies 2026-07-01T06:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/intensive-diabetes-management-program-eliminates-amputations-in-south-los-angeles-safety-net-hospital 2026-07-01T04:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensive-diabetes-management-program-eliminates-amputations-in-south-los-angeles-safety-net-hospital 2026-07-01T04:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/case-reports-reveal-individualized-risk-patterns-in-triple-negative-breast-cancer-treatment 2026-07-01T04:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/case-reports-reveal-individualized-risk-patterns-in-triple-negative-breast-cancer-treatment 2026-07-01T04:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/west-nile-virus-season-intensifies-california-reports-first-human-case-as-surveillance-signals-surge 2026-07-01T03:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/west-nile-virus-season-intensifies-california-reports-first-human-case-as-surveillance-signals-surge 2026-07-01T03:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/asco-warns-of-critical-ifosfamide-shortage-threatening-cancer-treatment 2026-07-01T01:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-warns-of-critical-ifosfamide-shortage-threatening-cancer-treatment 2026-07-01T01:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/abionyx-secures-up-to-eur33m-and-launches-pivotal-phase-2b-trial-of-cer-001-in-sepsis 2026-07-01T01:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abionyx-secures-up-to-eur33m-and-launches-pivotal-phase-2b-trial-of-cer-001-in-sepsis 2026-07-01T01:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-s-patent-office-finalizes-new-guidelines-for-medical-use-inventions-accepts-post-filing-data-but-maintains-restrictions-on-dosage-regimens 2026-07-01T00:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazil-s-patent-office-finalizes-new-guidelines-for-medical-use-inventions-accepts-post-filing-data-but-maintains-restrictions-on-dosage-regimens 2026-07-01T00:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/decoding-the-ptm-code-of-cgas-sting-in-gastric-cancer-from-innate-dna-sensing-to-precision-combination-therapy 2026-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/decoding-the-ptm-code-of-cgas-sting-in-gastric-cancer-from-innate-dna-sensing-to-precision-combination-therapy 2026-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mexico-city-unveils-us-125-million-biotech-investment-to-build-domestic-biopharmaceutical-manufacturing-capacity 2026-06-30T23:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mexico-city-unveils-us-125-million-biotech-investment-to-build-domestic-biopharmaceutical-manufacturing-capacity 2026-06-30T23:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/monoclonal-antibody-alt-100-shows-early-promise-for-ards-in-proof-of-concept-trial 2026-06-30T22:13:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monoclonal-antibody-alt-100-shows-early-promise-for-ards-in-proof-of-concept-trial 2026-06-30T22:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/virginia-s-leading-research-universities-unite-to-advance-biomedical-innovation 2026-06-30T22:13:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virginia-s-leading-research-universities-unite-to-advance-biomedical-innovation 2026-06-30T22:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/roche-reports-clinical-trial-success-for-lung-cancer-drug 2026-06-30T22:12:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-reports-clinical-trial-success-for-lung-cancer-drug 2026-06-30T22:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-supply-forecasting-why-data-currency-not-algorithms-drives-waste-reduction 2026-06-30T22:12:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-supply-forecasting-why-data-currency-not-algorithms-drives-waste-reduction 2026-06-30T22:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-launches-to-evaluate-atezolizumab-as-first-postoperative-therapy-for-stage-i-nsclc 2026-06-30T22:12:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-launches-to-evaluate-atezolizumab-as-first-postoperative-therapy-for-stage-i-nsclc 2026-06-30T22:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/candida-auris-drug-resistant-fungus-spreads-in-u-s-healthcare-facilities-cdc-reports 2026-06-30T21:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candida-auris-drug-resistant-fungus-spreads-in-u-s-healthcare-facilities-cdc-reports 2026-06-30T21:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-s-ziftomenib-earns-fda-approval-paving-path-for-expanded-aml-treatment-and-fti-comeback 2026-06-30T21:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-s-ziftomenib-earns-fda-approval-paving-path-for-expanded-aml-treatment-and-fti-comeback 2026-06-30T21:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/stravitz-sanyal-liver-institute-opens-30-million-clinical-research-imaging-center-to-accelerate-liver-and-metabolic-disease-drug-development 2026-06-30T21:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stravitz-sanyal-liver-institute-opens-30-million-clinical-research-imaging-center-to-accelerate-liver-and-metabolic-disease-drug-development 2026-06-30T21:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/ohio-state-launches-buckeye-biolaunch-an-ai-enabled-center-to-accelerate-therapeutic-discovery-and-commercialization 2026-06-30T21:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ohio-state-launches-buckeye-biolaunch-an-ai-enabled-center-to-accelerate-therapeutic-discovery-and-commercialization 2026-06-30T21:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/columbia-scientists-solve-47-year-mystery-of-malaria-invasion-design-first-invasion-blocking-mini-protein 2026-06-30T21:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/columbia-scientists-solve-47-year-mystery-of-malaria-invasion-design-first-invasion-blocking-mini-protein 2026-06-30T21:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/pep-club-launches-full-stack-telehealth-platform-integrating-prescription-therapy-peptide-protocols-and-at-home-biomarker-testing 2026-06-30T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pep-club-launches-full-stack-telehealth-platform-integrating-prescription-therapy-peptide-protocols-and-at-home-biomarker-testing 2026-06-30T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/richard-dalby-retires-after-34-years-shaping-pulmonary-and-nasal-drug-delivery-science-at-university-of-maryland 2026-06-30T21:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/richard-dalby-retires-after-34-years-shaping-pulmonary-and-nasal-drug-delivery-science-at-university-of-maryland 2026-06-30T21:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/hnklear-saliva-based-diagnostic-platform-advances-toward-clinical-use-in-head-and-neck-cancer 2026-06-30T21:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hnklear-saliva-based-diagnostic-platform-advances-toward-clinical-use-in-head-and-neck-cancer 2026-06-30T21:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/precision-nutrition-in-diabetic-foot-ulcers-ai-enabled-personalized-metabolic-management-remains-a-future-vision-not-current-reality 2026-06-30T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-nutrition-in-diabetic-foot-ulcers-ai-enabled-personalized-metabolic-management-remains-a-future-vision-not-current-reality 2026-06-30T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-bispecific-antibody-shuttles-unlock-dual-receptor-pathway-across-the-blood-brain-barrier 2026-06-30T20:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-bispecific-antibody-shuttles-unlock-dual-receptor-pathway-across-the-blood-brain-barrier 2026-06-30T20:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/egypt-launches-first-national-rare-diseases-forum-unveils-comprehensive-patient-support-strategy 2026-06-30T20:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egypt-launches-first-national-rare-diseases-forum-unveils-comprehensive-patient-support-strategy 2026-06-30T20:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/med-el-acquires-two-gene-therapy-programs-from-rescue-hearing-targeting-myo7a-and-strc-mutations-for-hearing-and-balance-disorders 2026-06-30T20:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/med-el-acquires-two-gene-therapy-programs-from-rescue-hearing-targeting-myo7a-and-strc-mutations-for-hearing-and-balance-disorders 2026-06-30T20:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/inductive-bio-launches-admet-prediction-connector-for-anthropic-s-claude-democratizing-ai-powered-drug-discovery 2026-06-30T19:09:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inductive-bio-launches-admet-prediction-connector-for-anthropic-s-claude-democratizing-ai-powered-drug-discovery 2026-06-30T19:09:55+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacists-warned-diverted-hiv-medicines-sold-on-online-p2p-platforms-pose-serious-patient-risk 2026-06-30T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacists-warned-diverted-hiv-medicines-sold-on-online-p2p-platforms-pose-serious-patient-risk 2026-06-30T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/dual-target-focused-ultrasound-delivers-immediate-relief-in-advanced-parkinson-s-as-bilateral-ptt-data-back-fda-approval 2026-06-30T19:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-target-focused-ultrasound-delivers-immediate-relief-in-advanced-parkinson-s-as-bilateral-ptt-data-back-fda-approval 2026-06-30T19:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/anti-lipid-antibodies-show-promise-for-earlier-lyme-disease-detection 2026-06-30T19:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-lipid-antibodies-show-promise-for-earlier-lyme-disease-detection 2026-06-30T19:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/gadi-lachman-trinetx-founder-joins-srotas-health-board-to-advance-ai-driven-clinical-trial-recruitment 2026-06-30T19:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gadi-lachman-trinetx-founder-joins-srotas-health-board-to-advance-ai-driven-clinical-trial-recruitment 2026-06-30T19:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/allucent-launches-ignitetm-site-network-to-accelerate-clinical-trial-execution-for-small-and-mid-sized-biopharma 2026-06-30T19:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allucent-launches-ignitetm-site-network-to-accelerate-clinical-trial-execution-for-small-and-mid-sized-biopharma 2026-06-30T19:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/infant-feeding-mode-shapes-gut-microbiome-composition-and-function-in-egyptian-neonates 2026-06-30T18:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infant-feeding-mode-shapes-gut-microbiome-composition-and-function-in-egyptian-neonates 2026-06-30T18:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-alerts-clinicians-to-surge-in-u-s-rabies-exposures-as-fatal-pediatric-case-highlights-pep-gaps 2026-06-30T18:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-alerts-clinicians-to-surge-in-u-s-rabies-exposures-as-fatal-pediatric-case-highlights-pep-gaps 2026-06-30T18:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/altasciences-completes-pivotal-toxicology-study-for-steel-therapeutics-fizurextm-clearing-path-to-ind-filing-for-anal-fissure-treatment 2026-06-30T18:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altasciences-completes-pivotal-toxicology-study-for-steel-therapeutics-fizurextm-clearing-path-to-ind-filing-for-anal-fissure-treatment 2026-06-30T18:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-launches-12-3-million-brain-frame-program-to-improve-brain-health-in-people-with-hiv-and-methamphetamine-use-disorder 2026-06-30T18:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-launches-12-3-million-brain-frame-program-to-improve-brain-health-in-people-with-hiv-and-methamphetamine-use-disorder 2026-06-30T18:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/fralin-biomedical-research-institute-awards-tenure-to-five-faculty-advancing-neuroscience-pulmonary-disease-and-health-behavior-research 2026-06-30T18:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fralin-biomedical-research-institute-awards-tenure-to-five-faculty-advancing-neuroscience-pulmonary-disease-and-health-behavior-research 2026-06-30T18:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/washington-university-launches-1-47m-trial-to-test-whether-insomnia-drug-suvorexant-can-slow-alzheimer-s-pathology 2026-06-30T18:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/washington-university-launches-1-47m-trial-to-test-whether-insomnia-drug-suvorexant-can-slow-alzheimer-s-pathology 2026-06-30T18:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/vector-science-therapeutics-files-provisional-patent-for-magnetic-patch-based-transdermal-peptide-delivery-platform 2026-06-30T18:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vector-science-therapeutics-files-provisional-patent-for-magnetic-patch-based-transdermal-peptide-delivery-platform 2026-06-30T18:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/dietary-protein-intake-shows-promise-for-reversing-hair-loss-clinical-evidence-and-expert-insights 2026-06-30T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dietary-protein-intake-shows-promise-for-reversing-hair-loss-clinical-evidence-and-expert-insights 2026-06-30T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/alr-technologies-to-acquire-cgm-medical-in-45-million-deal-securing-continuous-glucose-monitor-manufacturing 2026-06-30T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alr-technologies-to-acquire-cgm-medical-in-45-million-deal-securing-continuous-glucose-monitor-manufacturing 2026-06-30T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/nanosensor-distinguishes-autism-from-intellectual-disability-using-nitric-oxide-biomarker-in-patient-stem-cells 2026-06-30T17:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanosensor-distinguishes-autism-from-intellectual-disability-using-nitric-oxide-biomarker-in-patient-stem-cells 2026-06-30T17:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/early-qc-planning-is-the-make-or-break-factor-in-cell-and-gene-therapy-development 2026-06-30T16:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-qc-planning-is-the-make-or-break-factor-in-cell-and-gene-therapy-development 2026-06-30T16:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/dkfz-researchers-secure-erc-funding-to-advance-a-lock-and-kill-gene-therapy-for-glioblastoma 2026-06-30T16:09:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dkfz-researchers-secure-erc-funding-to-advance-a-lock-and-kill-gene-therapy-for-glioblastoma 2026-06-30T16:09:55+00:00 hourly 0.9 https://trial.medpath.com/news/uk-pharma-transparency-database-hits-record-ps929-6-million-in-2025-driven-by-r-d-growth-and-new-disclosure-guidance 2026-06-30T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-pharma-transparency-database-hits-record-ps929-6-million-in-2025-driven-by-r-d-growth-and-new-disclosure-guidance 2026-06-30T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/headlands-research-acquires-clinical-trials-research-bolstering-cardiometabolic-trial-capabilities-in-california 2026-06-30T16:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/headlands-research-acquires-clinical-trials-research-bolstering-cardiometabolic-trial-capabilities-in-california 2026-06-30T16:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/lancet-review-mrna-vaccines-94-effective-against-covid-19-death-serious-adverse-events-remain-rare-across-billions-of-doses 2026-06-30T16:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lancet-review-mrna-vaccines-94-effective-against-covid-19-death-serious-adverse-events-remain-rare-across-billions-of-doses 2026-06-30T16:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/creative-biolabs-launches-integrated-glycorna-analysis-platform-for-rna-glycobiology-and-biomarker-discovery 2026-06-30T16:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creative-biolabs-launches-integrated-glycorna-analysis-platform-for-rna-glycobiology-and-biomarker-discovery 2026-06-30T16:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/nih-s-all-of-us-program-releases-major-dataset-expansion-linking-535000-genomes-with-ehr-data-to-advance-precision-medicine 2026-06-30T16:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-s-all-of-us-program-releases-major-dataset-expansion-linking-535000-genomes-with-ehr-data-to-advance-precision-medicine 2026-06-30T16:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-kowa-s-pemafibrate-k-808-for-primary-biliary-cholangitis 2026-06-30T16:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-kowa-s-pemafibrate-k-808-for-primary-biliary-cholangitis 2026-06-30T16:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/ai-enabled-imaging-modalities-market-to-surge-from-3-62-billion-to-15-16-billion-by-2035-driven-by-deep-learning-and-hospital-demand 2026-06-30T15:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-enabled-imaging-modalities-market-to-surge-from-3-62-billion-to-15-16-billion-by-2035-driven-by-deep-learning-and-hospital-demand 2026-06-30T15:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/adragos-and-towa-forge-strategic-partnership-to-supply-1-5-billion-off-patent-tablets-annually-from-japan-facility 2026-06-30T15:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adragos-and-towa-forge-strategic-partnership-to-supply-1-5-billion-off-patent-tablets-annually-from-japan-facility 2026-06-30T15:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/tga-warns-multiple-sexual-enhancement-supplements-contain-hidden-prescription-drugs 2026-06-30T15:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tga-warns-multiple-sexual-enhancement-supplements-contain-hidden-prescription-drugs 2026-06-30T15:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/anixa-biosciences-wins-australian-patent-acceptance-for-breast-cancer-vaccine-expanding-global-ip-estate 2026-06-30T15:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anixa-biosciences-wins-australian-patent-acceptance-for-breast-cancer-vaccine-expanding-global-ip-estate 2026-06-30T15:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-neuroscience-completes-dosing-in-cohorts-3-and-4-of-phase-1-2a-aspiro-trial-for-parkinson-s-disease-cell-therapy 2026-06-30T15:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-neuroscience-completes-dosing-in-cohorts-3-and-4-of-phase-1-2a-aspiro-trial-for-parkinson-s-disease-cell-therapy 2026-06-30T15:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/flare-therapeutics-secures-85m-series-c-appoints-anna-protopapas-as-ceo-to-advance-first-in-class-aron-degrader-for-prostate-cancer 2026-06-30T15:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flare-therapeutics-secures-85m-series-c-appoints-anna-protopapas-as-ceo-to-advance-first-in-class-aron-degrader-for-prostate-cancer 2026-06-30T15:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/erc-awards-proof-of-concept-grants-to-182-researchers-including-three-at-tu-darmstadt 2026-06-30T14:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erc-awards-proof-of-concept-grants-to-182-researchers-including-three-at-tu-darmstadt 2026-06-30T14:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-files-patent-for-nectin-4-x-pd-l1-dual-targeting-backbone-to-expand-solid-tumor-strategy 2026-06-30T14:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptevo-files-patent-for-nectin-4-x-pd-l1-dual-targeting-backbone-to-expand-solid-tumor-strategy 2026-06-30T14:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-patients-with-metastatic-melanoma-face-life-threatening-delays-as-til-therapy-awaits-provincial-funding 2026-06-30T13:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-patients-with-metastatic-melanoma-face-life-threatening-delays-as-til-therapy-awaits-provincial-funding 2026-06-30T13:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/exonate-appoints-olav-hellebo-as-ceo-advances-topical-vegf-eye-drop-toward-phase-iib-trial 2026-06-30T13:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exonate-appoints-olav-hellebo-as-ceo-advances-topical-vegf-eye-drop-toward-phase-iib-trial 2026-06-30T13:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/global-experts-release-second-universal-definition-of-heart-failure-shifting-focus-to-early-detection-and-disease-trajectory 2026-06-30T13:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-experts-release-second-universal-definition-of-heart-failure-shifting-focus-to-early-detection-and-disease-trajectory 2026-06-30T13:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-unanimously-backs-moderna-s-mrna-flu-vaccine-setting-stage-for-first-mrna-seasonal-flu-shot 2026-06-30T13:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-panel-unanimously-backs-moderna-s-mrna-flu-vaccine-setting-stage-for-first-mrna-seasonal-flu-shot 2026-06-30T13:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-prosper-data-show-mogamulizumab-provides-rapid-sustained-symptom-relief-in-mycosis-fungoides-and-sezary-syndrome 2026-06-30T12:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-prosper-data-show-mogamulizumab-provides-rapid-sustained-symptom-relief-in-mycosis-fungoides-and-sezary-syndrome 2026-06-30T12:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/pennsylvania-s-drug-delivery-resulting-in-death-law-a-mother-s-fight-exposes-the-complex-reality-of-prosecuting-overdoses-as-homicides 2026-06-30T12:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pennsylvania-s-drug-delivery-resulting-in-death-law-a-mother-s-fight-exposes-the-complex-reality-of-prosecuting-overdoses-as-homicides 2026-06-30T12:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/multi-antigen-t-cell-therapy-shows-safety-and-durable-responses-in-pediatric-brain-tumors-phase-1-remind-trial 2026-06-30T12:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-antigen-t-cell-therapy-shows-safety-and-durable-responses-in-pediatric-brain-tumors-phase-1-remind-trial 2026-06-30T12:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/tumour-glycolysis-drives-vascular-dysfunction-and-immunotherapy-resistance-preclinical-study-shows 2026-06-30T12:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumour-glycolysis-drives-vascular-dysfunction-and-immunotherapy-resistance-preclinical-study-shows 2026-06-30T12:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/post-meal-fiber-shots-and-glucose-gummies-navigating-the-metabolic-wellness-market-without-medical-claims 2026-06-30T12:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/post-meal-fiber-shots-and-glucose-gummies-navigating-the-metabolic-wellness-market-without-medical-claims 2026-06-30T12:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/pfas-free-alternatives-exist-for-87-of-human-medicines-landmark-university-of-freiburg-report-finds 2026-06-30T11:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfas-free-alternatives-exist-for-87-of-human-medicines-landmark-university-of-freiburg-report-finds 2026-06-30T11:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/sirpad-sirolimus-coated-balloons-cut-amputation-and-revascularization-in-infrainguinal-pad 2026-06-30T11:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirpad-sirolimus-coated-balloons-cut-amputation-and-revascularization-in-infrainguinal-pad 2026-06-30T11:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/metis-techbio-licenses-ai-designed-trispecific-t-cell-engager-mts-128-to-boulevard-bio-in-deal-worth-up-to-1-6-billion 2026-06-30T11:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-techbio-licenses-ai-designed-trispecific-t-cell-engager-mts-128-to-boulevard-bio-in-deal-worth-up-to-1-6-billion 2026-06-30T11:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/kff-poll-lack-of-trusted-provider-and-social-media-use-linked-to-vaccine-myth-belief 2026-06-30T10:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kff-poll-lack-of-trusted-provider-and-social-media-use-linked-to-vaccine-myth-belief 2026-06-30T10:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/me-cfs-research-foundation-invests-eur2-4-million-in-seven-new-research-projects-across-germany 2026-06-30T09:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/me-cfs-research-foundation-invests-eur2-4-million-in-seven-new-research-projects-across-germany 2026-06-30T09:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-nexviazyme-meets-all-endpoints-in-phase-iii-baby-comet-trial-for-infantile-onset-pompe-disease 2026-06-30T09:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-nexviazyme-meets-all-endpoints-in-phase-iii-baby-comet-trial-for-infantile-onset-pompe-disease 2026-06-30T09:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/embl-spin-off-epitome-therapeutics-launches-with-eur4m-to-pioneer-precision-epigenome-editing-for-gene-activation 2026-06-30T09:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/embl-spin-off-epitome-therapeutics-launches-with-eur4m-to-pioneer-precision-epigenome-editing-for-gene-activation 2026-06-30T09:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/creatine-as-an-add-on-therapy-for-depression-systematic-review-reveals-mixed-evidence-calls-for-larger-trials 2026-06-30T09:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creatine-as-an-add-on-therapy-for-depression-systematic-review-reveals-mixed-evidence-calls-for-larger-trials 2026-06-30T09:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/closing-the-scale-up-gap-manufacturing-challenges-and-innovations-in-cell-and-gene-therapy 2026-06-30T08:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/closing-the-scale-up-gap-manufacturing-challenges-and-innovations-in-cell-and-gene-therapy 2026-06-30T08:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-based-biologics-emerge-as-promising-strategy-for-vascular-repair-amid-persistent-translational-hurdles 2026-06-30T07:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-based-biologics-emerge-as-promising-strategy-for-vascular-repair-amid-persistent-translational-hurdles 2026-06-30T07:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/space-travel-does-not-significantly-impair-cardiac-sarcomere-function-but-triggers-immune-related-proteomic-changes 2026-06-30T07:11:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/space-travel-does-not-significantly-impair-cardiac-sarcomere-function-but-triggers-immune-related-proteomic-changes 2026-06-30T07:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-s-ab8939-plus-venetoclax-achieves-67-orr-in-phase-1-trial-for-high-risk-relapsed-refractory-aml 2026-06-30T07:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ab-science-s-ab8939-plus-venetoclax-achieves-67-orr-in-phase-1-trial-for-high-risk-relapsed-refractory-aml 2026-06-30T07:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-roche-s-enspryng-as-first-at-home-subcutaneous-therapy-for-thyroid-eye-disease 2026-06-30T07:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-roche-s-enspryng-as-first-at-home-subcutaneous-therapy-for-thyroid-eye-disease 2026-06-30T07:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/adjane-s-intranasal-nomv-vaccine-platform-shows-first-human-proof-of-concept-for-mucosal-immunity 2026-06-30T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjane-s-intranasal-nomv-vaccine-platform-shows-first-human-proof-of-concept-for-mucosal-immunity 2026-06-30T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/senator-hassan-opens-investigation-into-merck-s-keytruda-patent-strategy-amid-pricing-concerns 2026-06-30T06:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senator-hassan-opens-investigation-into-merck-s-keytruda-patent-strategy-amid-pricing-concerns 2026-06-30T06:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/nectin-4-targeted-pet-tracer-68ga-ga-fz-nr-1-outperforms-fdg-in-recurrent-or-metastatic-triple-negative-breast-cancer 2026-06-30T02:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nectin-4-targeted-pet-tracer-68ga-ga-fz-nr-1-outperforms-fdg-in-recurrent-or-metastatic-triple-negative-breast-cancer 2026-06-30T02:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-nears-pivotal-phase-3-readout-for-galinpepimut-s-in-aml-as-regal-trial-approaches-final-analysis 2026-06-30T02:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-nears-pivotal-phase-3-readout-for-galinpepimut-s-in-aml-as-regal-trial-approaches-final-analysis 2026-06-30T02:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/human-3d-organoid-models-advance-mechanistic-understanding-of-motor-neuron-diseases 2026-06-30T00:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/human-3d-organoid-models-advance-mechanistic-understanding-of-motor-neuron-diseases 2026-06-30T00:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-comprehensive-cancer-center-showcases-smart-nanotechnology-precision-imaging-and-high-risk-lymphoma-trial-in-summer-2026-synthesis-magazine 2026-06-30T00:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-comprehensive-cancer-center-showcases-smart-nanotechnology-precision-imaging-and-high-risk-lymphoma-trial-in-summer-2026-synthesis-magazine 2026-06-30T00:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-team-awarded-200000-aspire-grant-to-target-npepps-enzyme-and-overcome-dual-resistance-to-chemotherapy-and-immunotherapy 2026-06-29T23:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-team-awarded-200000-aspire-grant-to-target-npepps-enzyme-and-overcome-dual-resistance-to-chemotherapy-and-immunotherapy 2026-06-29T23:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/study-links-sedentary-lifestyle-to-early-mitochondrial-dysfunction-in-healthy-adults 2026-06-29T23:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-links-sedentary-lifestyle-to-early-mitochondrial-dysfunction-in-healthy-adults 2026-06-29T23:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/powassan-virus-cases-reach-record-high-of-76-in-2025-as-tick-borne-threat-expands-across-us 2026-06-29T23:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/powassan-virus-cases-reach-record-high-of-76-in-2025-as-tick-borne-threat-expands-across-us 2026-06-29T23:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/virginia-approves-funding-for-vcu-to-acquire-altria-center-and-build-new-school-of-dentistry-facility 2026-06-29T22:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virginia-approves-funding-for-vcu-to-acquire-altria-center-and-build-new-school-of-dentistry-facility 2026-06-29T22:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/second-primary-malignancies-emerge-as-clinically-relevant-complication-of-t-cell-engaging-bispecific-antibody-therapy 2026-06-29T22:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-primary-malignancies-emerge-as-clinically-relevant-complication-of-t-cell-engaging-bispecific-antibody-therapy 2026-06-29T22:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/tumour-genetic-variants-linked-to-immunotherapy-toxicity-risk-in-urothelial-cancer 2026-06-29T22:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumour-genetic-variants-linked-to-immunotherapy-toxicity-risk-in-urothelial-cancer 2026-06-29T22:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/eu-biotech-act-proposes-sweeping-clinical-trial-reforms-to-reverse-europe-s-declining-global-competitiveness 2026-06-29T22:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-biotech-act-proposes-sweeping-clinical-trial-reforms-to-reverse-europe-s-declining-global-competitiveness 2026-06-29T22:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/google-cloud-to-offer-sandboxaq-s-large-quantitative-ai-models-for-drug-discovery-via-marketplace 2026-06-29T21:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-cloud-to-offer-sandboxaq-s-large-quantitative-ai-models-for-drug-discovery-via-marketplace 2026-06-29T21:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacist-led-medication-optimization-tied-to-19-4-lower-medical-costs-in-medicare-aco-population 2026-06-29T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacist-led-medication-optimization-tied-to-19-4-lower-medical-costs-in-medicare-aco-population 2026-06-29T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-selects-eli-lilly-regeneron-among-first-seven-companies-for-precheck-manufacturing-pilot-program 2026-06-29T21:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-selects-eli-lilly-regeneron-among-first-seven-companies-for-precheck-manufacturing-pilot-program 2026-06-29T21:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/connie-cepko-retires-after-pioneering-gene-agnostic-therapies-for-inherited-retinal-disease 2026-06-29T20:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/connie-cepko-retires-after-pioneering-gene-agnostic-therapies-for-inherited-retinal-disease 2026-06-29T20:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/former-nfl-star-chris-johnson-reveals-als-diagnosis-joins-experimental-clinical-trial 2026-06-29T19:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-nfl-star-chris-johnson-reveals-als-diagnosis-joins-experimental-clinical-trial 2026-06-29T19:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/diabetes-linked-to-worse-long-covid-recovery-higher-cardiovascular-risk-after-hospitalisation 2026-06-29T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diabetes-linked-to-worse-long-covid-recovery-higher-cardiovascular-risk-after-hospitalisation 2026-06-29T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/moatrx-launches-axlrx-ai-pharma-intelligence-platform-for-commercial-consulting 2026-06-29T19:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moatrx-launches-axlrx-ai-pharma-intelligence-platform-for-commercial-consulting 2026-06-29T19:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/spinal-cord-stimulation-shows-32-arm-strength-gain-in-stroke-pilot-trial 2026-06-29T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spinal-cord-stimulation-shows-32-arm-strength-gain-in-stroke-pilot-trial 2026-06-29T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/algeria-s-national-cancer-plan-2035-a-strategic-roadmap-for-prevention-early-detection-and-equitable-oncology-care 2026-06-29T18:10:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algeria-s-national-cancer-plan-2035-a-strategic-roadmap-for-prevention-early-detection-and-equitable-oncology-care 2026-06-29T18:10:42+00:00 hourly 0.9 https://trial.medpath.com/news/anlotinib-combined-with-pd-1-inhibitor-suppresses-mss-colorectal-cancer-via-vascular-normalization-and-immune-reprogramming 2026-06-29T18:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anlotinib-combined-with-pd-1-inhibitor-suppresses-mss-colorectal-cancer-via-vascular-normalization-and-immune-reprogramming 2026-06-29T18:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-nears-aml-trial-readout-moderna-expands-oncology-pipeline-and-abcellera-lands-jazz-partnership-as-biotech-stocks-hit-52-week-highs 2026-06-29T18:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-nears-aml-trial-readout-moderna-expands-oncology-pipeline-and-abcellera-lands-jazz-partnership-as-biotech-stocks-hit-52-week-highs 2026-06-29T18:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/suic-and-visionrenu-sign-strategic-mou-to-accelerate-ai-powered-biotechnology-and-precision-medicine 2026-06-29T18:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/suic-and-visionrenu-sign-strategic-mou-to-accelerate-ai-powered-biotechnology-and-precision-medicine 2026-06-29T18:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/microvilli-trapping-of-pd-1-limits-immunotherapy-efficacy-engineered-antibody-offers-new-solution 2026-06-29T17:09:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microvilli-trapping-of-pd-1-limits-immunotherapy-efficacy-engineered-antibody-offers-new-solution 2026-06-29T17:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-based-immunoassays-market-poised-to-reach-11-55-billion-by-2030-driven-by-ai-integration-and-rising-cancer-incidence 2026-06-29T17:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-based-immunoassays-market-poised-to-reach-11-55-billion-by-2030-driven-by-ai-integration-and-rising-cancer-incidence 2026-06-29T17:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/scaling-organoids-for-drug-discovery-how-automation-and-ai-are-transforming-the-dmta-cycle 2026-06-29T17:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scaling-organoids-for-drug-discovery-how-automation-and-ai-are-transforming-the-dmta-cycle 2026-06-29T17:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-high-content-screening-accelerates-phenotypic-profiling-with-up-to-100-faster-image-acquisition 2026-06-29T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-high-content-screening-accelerates-phenotypic-profiling-with-up-to-100-faster-image-acquisition 2026-06-29T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/uk-invests-ps9-7m-to-strengthen-clinical-research-careers-across-the-nhs 2026-06-29T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-invests-ps9-7m-to-strengthen-clinical-research-careers-across-the-nhs 2026-06-29T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/nature-medicine-highlights-nordic-ai-health-infrastructure-with-karolinska-institutet-as-key-enabler 2026-06-29T17:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-medicine-highlights-nordic-ai-health-infrastructure-with-karolinska-institutet-as-key-enabler 2026-06-29T17:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/medetomidine-a-potent-veterinary-sedative-emerges-as-a-dangerous-adulterant-in-illicit-fentanyl-supply-coroners-warn 2026-06-29T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medetomidine-a-potent-veterinary-sedative-emerges-as-a-dangerous-adulterant-in-illicit-fentanyl-supply-coroners-warn 2026-06-29T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/bipartisan-senate-push-revives-35-insulin-cap-for-private-insurance-and-uninsured-patients 2026-06-29T16:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bipartisan-senate-push-revives-35-insulin-cap-for-private-insurance-and-uninsured-patients 2026-06-29T16:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/cansinobio-s-quadrivalent-meningococcal-conjugate-vaccine-menhycia-r-receives-registration-approval-in-argentina 2026-06-29T16:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cansinobio-s-quadrivalent-meningococcal-conjugate-vaccine-menhycia-r-receives-registration-approval-in-argentina 2026-06-29T16:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-shows-significant-tissue-level-improvements-in-phase-2-trial-for-eosinophilic-gastritis 2026-06-29T16:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-shows-significant-tissue-level-improvements-in-phase-2-trial-for-eosinophilic-gastritis 2026-06-29T16:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/california-s-8-4-billion-immunology-research-bond-heads-to-voters-amid-federal-funding-crisis 2026-06-29T15:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-s-8-4-billion-immunology-research-bond-heads-to-voters-amid-federal-funding-crisis 2026-06-29T15:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/flow-imaging-microscopy-bridges-the-gap-in-subvisible-particle-testing-for-biologics-usp-stimuli-article-says 2026-06-29T15:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flow-imaging-microscopy-bridges-the-gap-in-subvisible-particle-testing-for-biologics-usp-stimuli-article-says 2026-06-29T15:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-expansion-of-biodexa-s-serenta-phase-3-trial-for-familial-adenomatous-polyposis 2026-06-29T14:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-expansion-of-biodexa-s-serenta-phase-3-trial-for-familial-adenomatous-polyposis 2026-06-29T14:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/ista-researchers-develop-experiment-guided-alphafold-to-capture-protein-dynamics 2026-06-29T14:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ista-researchers-develop-experiment-guided-alphafold-to-capture-protein-dynamics 2026-06-29T14:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/dyadic-secures-japanese-patent-for-c1-recombinant-protein-platform-accelerates-asia-pacific-expansion 2026-06-29T14:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyadic-secures-japanese-patent-for-c1-recombinant-protein-platform-accelerates-asia-pacific-expansion 2026-06-29T14:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/the-right-way-to-tackle-developing-countries-cancer-crisis-why-weakening-ip-protections-is-not-the-answer 2026-06-29T13:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-right-way-to-tackle-developing-countries-cancer-crisis-why-weakening-ip-protections-is-not-the-answer 2026-06-29T13:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-psoriasis-care-evolves-toward-multimodal-diagnosis-and-personalized-treatment-bibliometric-analysis-reveals 2026-06-29T13:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-psoriasis-care-evolves-toward-multimodal-diagnosis-and-personalized-treatment-bibliometric-analysis-reveals 2026-06-29T13:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/alebund-pharmaceuticals-debuts-on-hong-kong-stock-exchange-raising-164-million-to-advance-broad-renal-pipeline 2026-06-29T13:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alebund-pharmaceuticals-debuts-on-hong-kong-stock-exchange-raising-164-million-to-advance-broad-renal-pipeline 2026-06-29T13:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-genomic-profiling-in-nsclc-lab-processing-improves-but-biopsy-to-order-delays-persist 2026-06-29T13:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-genomic-profiling-in-nsclc-lab-processing-improves-but-biopsy-to-order-delays-persist 2026-06-29T13:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/a-retired-drug-researcher-s-journey-through-alzheimer-s-diagnosis-highlights-gaps-in-patient-access-to-early-information 2026-06-29T13:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-retired-drug-researcher-s-journey-through-alzheimer-s-diagnosis-highlights-gaps-in-patient-access-to-early-information 2026-06-29T13:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/body-fluid-analysis-market-projected-to-reach-3-65-billion-by-2031-driven-by-biomarker-based-diagnostics-and-laboratory-automation 2026-06-29T12:12:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/body-fluid-analysis-market-projected-to-reach-3-65-billion-by-2031-driven-by-biomarker-based-diagnostics-and-laboratory-automation 2026-06-29T12:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/talawar-therapeutics-to-go-public-via-spac-merger-secures-225m-pipe-to-advance-bispecific-antibody-for-atopic-dermatitis 2026-06-29T12:12:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/talawar-therapeutics-to-go-public-via-spac-merger-secures-225m-pipe-to-advance-bispecific-antibody-for-atopic-dermatitis 2026-06-29T12:12:14+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-reports-positive-phase-3-results-for-vr-205-in-japanese-adults-with-iga-nephropathy-targets-2026-nda-submission 2026-06-29T12:11:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-reports-positive-phase-3-results-for-vr-205-in-japanese-adults-with-iga-nephropathy-targets-2026-nda-submission 2026-06-29T12:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-recommends-hopledo-ipx203-for-parkinson-s-disease-with-motor-fluctuations-paving-way-for-eu-approval 2026-06-29T12:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-recommends-hopledo-ipx203-for-parkinson-s-disease-with-motor-fluctuations-paving-way-for-eu-approval 2026-06-29T12:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/repeated-high-voltage-pulsed-radiofrequency-reduces-postherpetic-neuralgia-incidence-in-diabetic-patients-with-thoracic-herpes-zoster 2026-06-29T12:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repeated-high-voltage-pulsed-radiofrequency-reduces-postherpetic-neuralgia-incidence-in-diabetic-patients-with-thoracic-herpes-zoster 2026-06-29T12:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-roadmap-targets-28000-discarded-donor-organs-annually-via-machine-perfusion-window 2026-06-29T12:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-roadmap-targets-28000-discarded-donor-organs-annually-via-machine-perfusion-window 2026-06-29T12:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/gist-and-k-medi-hub-secure-national-funding-to-develop-oral-cd73-targeting-immuno-oncology-drug 2026-06-29T11:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gist-and-k-medi-hub-secure-national-funding-to-develop-oral-cd73-targeting-immuno-oncology-drug 2026-06-29T11:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/natera-and-aveta-biomics-partner-on-global-phase-3-trial-of-oral-immunotherapy-apg-157-in-head-and-neck-cancer 2026-06-29T11:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-and-aveta-biomics-partner-on-global-phase-3-trial-of-oral-immunotherapy-apg-157-in-head-and-neck-cancer 2026-06-29T11:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/ever-supreme-s-allogeneic-car-t-car001-clears-phase-i-safety-review-advances-to-phase-iia-in-solid-tumors 2026-06-29T11:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ever-supreme-s-allogeneic-car-t-car001-clears-phase-i-safety-review-advances-to-phase-iia-in-solid-tumors 2026-06-29T11:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-axelios-1-a-next-generation-sequencing-platform-delivering-same-day-whole-genome-results 2026-06-29T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-axelios-1-a-next-generation-sequencing-platform-delivering-same-day-whole-genome-results 2026-06-29T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/one-person-a-week-dies-with-undiagnosed-tb-in-england-study-finds 2026-06-29T11:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-person-a-week-dies-with-undiagnosed-tb-in-england-study-finds 2026-06-29T11:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/clive-meanwell-bets-on-ai-to-replicate-metsera-style-bidding-war-success-in-population-health 2026-06-29T11:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clive-meanwell-bets-on-ai-to-replicate-metsera-style-bidding-war-success-in-population-health 2026-06-29T11:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/tolerogenixx-completes-last-patient-transplant-in-phase-iib-tol-2-trial-of-mic-lx-a-first-in-class-immune-tolerance-cell-therapy-for-kidney-transplantation 2026-06-29T09:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tolerogenixx-completes-last-patient-transplant-in-phase-iib-tol-2-trial-of-mic-lx-a-first-in-class-immune-tolerance-cell-therapy-for-kidney-transplantation 2026-06-29T09:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/doset-new-adaptive-trial-design-improves-dose-optimization-for-car-t-cell-therapy-in-early-phase-cancer-studies 2026-06-29T08:10:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doset-new-adaptive-trial-design-improves-dose-optimization-for-car-t-cell-therapy-in-early-phase-cancer-studies 2026-06-29T08:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/parp-inhibitors-expand-beyond-brca-mutated-cancers-emerging-evidence-across-solid-tumors-and-combination-strategies 2026-06-29T08:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parp-inhibitors-expand-beyond-brca-mutated-cancers-emerging-evidence-across-solid-tumors-and-combination-strategies 2026-06-29T08:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-signals-launches-signals-ai-agentic-framework-to-transform-r-d-data-into-actionable-scientific-insights 2026-06-29T08:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revvity-signals-launches-signals-ai-agentic-framework-to-transform-r-d-data-into-actionable-scientific-insights 2026-06-29T08:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/zelluna-doses-first-patient-with-world-s-first-mage-a4-targeting-tcr-nk-therapy-in-phase-1-solid-tumour-trial 2026-06-29T07:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zelluna-doses-first-patient-with-world-s-first-mage-a4-targeting-tcr-nk-therapy-in-phase-1-solid-tumour-trial 2026-06-29T07:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-acquires-kartos-therapeutics-for-450m-to-develop-navtemadlin-an-mdm2-inhibitor-for-myelofibrosis 2026-06-29T06:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-acquires-kartos-therapeutics-for-450m-to-develop-navtemadlin-an-mdm2-inhibitor-for-myelofibrosis 2026-06-29T06:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/professor-gina-ravenscroft-appointed-inaugural-dr-patricia-kailis-chair-in-rare-diseases-at-uwa 2026-06-29T06:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/professor-gina-ravenscroft-appointed-inaugural-dr-patricia-kailis-chair-in-rare-diseases-at-uwa 2026-06-29T06:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/excess-visceral-fat-linked-to-accelerated-biological-ageing-study-finds 2026-06-29T06:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excess-visceral-fat-linked-to-accelerated-biological-ageing-study-finds 2026-06-29T06:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/lab-grown-retinas-to-advance-gene-therapy-for-inherited-blindness-win-nsw-government-grant 2026-06-29T04:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lab-grown-retinas-to-advance-gene-therapy-for-inherited-blindness-win-nsw-government-grant 2026-06-29T04:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/india-expands-mandatory-qr-code-traceability-to-all-vaccines-antimicrobials-narcotics-and-anti-cancer-drugs 2026-06-29T04:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-expands-mandatory-qr-code-traceability-to-all-vaccines-antimicrobials-narcotics-and-anti-cancer-drugs 2026-06-29T04:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/nasal-commensal-viruses-may-drive-allergic-rhinitis-ribavirin-spray-shows-early-promise-in-phase-2-trial 2026-06-29T02:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasal-commensal-viruses-may-drive-allergic-rhinitis-ribavirin-spray-shows-early-promise-in-phase-2-trial 2026-06-29T02:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/gc-wellbeing-licenses-raziel-s-next-generation-fat-dissolving-injectable-eyes-phase-3-entry 2026-06-29T01:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-wellbeing-licenses-raziel-s-next-generation-fat-dissolving-injectable-eyes-phase-3-entry 2026-06-29T01:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/new-sensor-listens-to-mini-hearts-poised-to-transform-cardiac-drug-development 2026-06-29T00:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-sensor-listens-to-mini-hearts-poised-to-transform-cardiac-drug-development 2026-06-29T00:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-startup-pormedtec-to-launch-japan-s-first-pig-to-human-kidney-transplant-clinical-trials-by-2028 2026-06-29T00:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-startup-pormedtec-to-launch-japan-s-first-pig-to-human-kidney-transplant-clinical-trials-by-2028 2026-06-29T00:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/magnesium-supplements-show-limited-clinical-benefit-in-healthy-populations-experts-emphasize-dietary-sources 2026-06-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnesium-supplements-show-limited-clinical-benefit-in-healthy-populations-experts-emphasize-dietary-sources 2026-06-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/senator-bill-cassidy-accuses-hhs-secretary-rfk-jr-of-lying-about-vaccine-autism-commitments-warns-of-erosion-in-public-health-trust 2026-06-28T23:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senator-bill-cassidy-accuses-hhs-secretary-rfk-jr-of-lying-about-vaccine-autism-commitments-warns-of-erosion-in-public-health-trust 2026-06-28T23:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/5-million-americans-drop-aca-coverage-after-enhanced-subsidies-expire-raising-public-health-concerns 2026-06-28T23:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/5-million-americans-drop-aca-coverage-after-enhanced-subsidies-expire-raising-public-health-concerns 2026-06-28T23:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/venture-capital-surge-propels-catalonia-s-life-sciences-sector-to-record-investment-heights 2026-06-28T20:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/venture-capital-surge-propels-catalonia-s-life-sciences-sector-to-record-investment-heights 2026-06-28T20:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/plasma-inflammation-profiles-linked-to-cognition-via-distinct-pathways-in-alzheimer-s-disease 2026-06-28T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plasma-inflammation-profiles-linked-to-cognition-via-distinct-pathways-in-alzheimer-s-disease 2026-06-28T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/rising-tide-of-phone-addiction-prompts-new-treatment-approaches-as-uk-clinics-report-surge-in-digital-dependency 2026-06-28T20:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rising-tide-of-phone-addiction-prompts-new-treatment-approaches-as-uk-clinics-report-surge-in-digital-dependency 2026-06-28T20:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/histotripsy-gains-traction-as-noninvasive-ultrasound-based-liver-tumor-ablation-expands-across-u-s-centers 2026-06-28T19:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histotripsy-gains-traction-as-noninvasive-ultrasound-based-liver-tumor-ablation-expands-across-u-s-centers 2026-06-28T19:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-agi-smart-city-clinical-trial-opens-enrollment-for-veterans-and-mental-health-populations 2026-06-28T19:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-agi-smart-city-clinical-trial-opens-enrollment-for-veterans-and-mental-health-populations 2026-06-28T19:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-eligibility-criteria-deny-secondary-breast-cancer-patient-access-to-promising-drug-forcing-ps200000-private-fundraising-campaign 2026-06-28T18:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-eligibility-criteria-deny-secondary-breast-cancer-patient-access-to-promising-drug-forcing-ps200000-private-fundraising-campaign 2026-06-28T18:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/iran-approves-whartocell-an-off-the-shelf-allogeneic-umbilical-cord-stem-cell-therapy-for-osteoarthritis 2026-06-28T18:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iran-approves-whartocell-an-off-the-shelf-allogeneic-umbilical-cord-stem-cell-therapy-for-osteoarthritis 2026-06-28T18:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/gut-fungi-linked-to-pediatric-allergic-disease-development-landmark-studies-reveal 2026-06-28T18:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-fungi-linked-to-pediatric-allergic-disease-development-landmark-studies-reveal 2026-06-28T18:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/young-cancer-survivor-inspired-by-suffolk-doctors-to-pursue-medicine 2026-06-28T18:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/young-cancer-survivor-inspired-by-suffolk-doctors-to-pursue-medicine 2026-06-28T18:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/low-intensity-ultrasound-may-shift-immune-cells-toward-healing-offering-a-non-invasive-strategy-against-post-traumatic-osteoarthritis 2026-06-28T15:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-intensity-ultrasound-may-shift-immune-cells-toward-healing-offering-a-non-invasive-strategy-against-post-traumatic-osteoarthritis 2026-06-28T15:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/yuhan-corporation-presents-phase-1b-results-for-novel-anti-ige-allergy-drug-lesigercept-at-eaaci-2026 2026-06-28T14:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yuhan-corporation-presents-phase-1b-results-for-novel-anti-ige-allergy-drug-lesigercept-at-eaaci-2026 2026-06-28T14:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-recalls-nearly-1-million-bottles-of-corlanor-and-sensipar-over-foreign-matter-contamination 2026-06-28T14:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-recalls-nearly-1-million-bottles-of-corlanor-and-sensipar-over-foreign-matter-contamination 2026-06-28T14:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-life-sciences-investments-plunge-40-in-2025-amid-geopolitical-headwinds-ai-driven-drug-development-emerges-as-bright-spot 2026-06-28T12:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/israeli-life-sciences-investments-plunge-40-in-2025-amid-geopolitical-headwinds-ai-driven-drug-development-emerges-as-bright-spot 2026-06-28T12:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/the-broken-math-of-drug-pricing-how-a-1000-a-day-hepatitis-c-cure-exposed-the-value-gap-in-u-s-pharmaceuticals 2026-06-28T12:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-broken-math-of-drug-pricing-how-a-1000-a-day-hepatitis-c-cure-exposed-the-value-gap-in-u-s-pharmaceuticals 2026-06-28T12:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/china-issues-world-s-first-ai-bci-eeg-data-standard-as-fda-and-ema-lag 2026-06-28T12:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-issues-world-s-first-ai-bci-eeg-data-standard-as-fda-and-ema-lag 2026-06-28T12:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/seven-maternal-deaths-in-rajasthan-trigger-nationwide-oxytocin-safety-probe-who-seeks-report 2026-06-28T12:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seven-maternal-deaths-in-rajasthan-trigger-nationwide-oxytocin-safety-probe-who-seeks-report 2026-06-28T12:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/nanox-reports-q1-2026-revenue-growth-withdraws-annual-guidance-amid-slower-commercialization 2026-06-28T11:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanox-reports-q1-2026-revenue-growth-withdraws-annual-guidance-amid-slower-commercialization 2026-06-28T11:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/intraoperative-frozen-section-analysis-after-neoadjuvant-chemotherapy-leads-to-unnecessary-alnd-in-node-negative-breast-cancer-patients 2026-06-28T10:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intraoperative-frozen-section-analysis-after-neoadjuvant-chemotherapy-leads-to-unnecessary-alnd-in-node-negative-breast-cancer-patients 2026-06-28T10:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/ai-identifies-distinct-migraine-patient-patterns-beyond-headache-symptoms 2026-06-28T10:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-identifies-distinct-migraine-patient-patterns-beyond-headache-symptoms 2026-06-28T10:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/bernstein-resumes-thermo-fisher-coverage-sees-improving-life-science-tools-sector 2026-06-28T07:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bernstein-resumes-thermo-fisher-coverage-sees-improving-life-science-tools-sector 2026-06-28T07:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-research-advances-and-hawaii-s-legislative-action-take-center-stage-at-2026-brain-health-summit 2026-06-28T05:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-research-advances-and-hawaii-s-legislative-action-take-center-stage-at-2026-brain-health-summit 2026-06-28T05:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/experts-call-for-strengthened-pandemic-preparedness-one-health-approach-and-combating-antimicrobial-resistance 2026-06-28T03:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-call-for-strengthened-pandemic-preparedness-one-health-approach-and-combating-antimicrobial-resistance 2026-06-28T03:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/75-year-old-chinese-grandfather-becomes-beauty-influencer-to-fund-grandson-s-sma-gene-therapy 2026-06-28T02:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/75-year-old-chinese-grandfather-becomes-beauty-influencer-to-fund-grandson-s-sma-gene-therapy 2026-06-28T02:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-launches-sephience-for-pku-with-125m-in-q1-sales-and-500m-convertible-note-offering 2026-06-28T00:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-launches-sephience-for-pku-with-125m-in-q1-sales-and-500m-convertible-note-offering 2026-06-28T00:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/enliven-therapeutics-advances-elvn-001-toward-pivotal-phase-3-trial-in-cml-amid-strong-financial-position 2026-06-27T23:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enliven-therapeutics-advances-elvn-001-toward-pivotal-phase-3-trial-in-cml-amid-strong-financial-position 2026-06-27T23:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/unilag-and-nafdac-call-for-scientific-validation-and-regulation-of-african-traditional-medicine 2026-06-27T23:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unilag-and-nafdac-call-for-scientific-validation-and-regulation-of-african-traditional-medicine 2026-06-27T23:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/redwire-opens-indiana-facility-to-advance-microgravity-based-drug-development 2026-06-27T22:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redwire-opens-indiana-facility-to-advance-microgravity-based-drug-development 2026-06-27T22:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/oruka-therapeutics-rides-orka-001-psoriasis-data-momentum-as-key-everlast-a-readout-looms 2026-06-27T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oruka-therapeutics-rides-orka-001-psoriasis-data-momentum-as-key-everlast-a-readout-looms 2026-06-27T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/blood-metabolism-maps-how-lifestyle-tracks-function-in-cognitive-aging 2026-06-27T21:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-metabolism-maps-how-lifestyle-tracks-function-in-cognitive-aging 2026-06-27T21:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/how-a-tech-founder-used-ai-to-navigate-a-rare-lymphoma-diagnosis-and-avoid-unnecessary-radiotherapy 2026-06-27T20:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-a-tech-founder-used-ai-to-navigate-a-rare-lymphoma-diagnosis-and-avoid-unnecessary-radiotherapy 2026-06-27T20:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/neuphoria-confirms-merger-talks-with-scancell-as-uk-biotech-eyes-nasdaq-listing 2026-06-27T20:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuphoria-confirms-merger-talks-with-scancell-as-uk-biotech-eyes-nasdaq-listing 2026-06-27T20:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/multi-decade-analysis-reveals-shifting-patterns-of-subsequent-primary-cancer-risk-among-survivors 2026-06-27T20:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-decade-analysis-reveals-shifting-patterns-of-subsequent-primary-cancer-risk-among-survivors 2026-06-27T20:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/long-island-oncology-ceo-jeff-vacirca-emerges-as-fda-commissioner-candidate-amid-agency-leadership-vacuum 2026-06-27T20:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-island-oncology-ceo-jeff-vacirca-emerges-as-fda-commissioner-candidate-amid-agency-leadership-vacuum 2026-06-27T20:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-testing-emerges-as-a-preventive-diagnostic-tool-for-mexico-s-chronic-disease-crisis 2026-06-27T19:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiome-testing-emerges-as-a-preventive-diagnostic-tool-for-mexico-s-chronic-disease-crisis 2026-06-27T19:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/sidra-medicine-launches-specialized-microbiome-service-to-advance-precision-care-for-women-and-children 2026-06-27T19:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sidra-medicine-launches-specialized-microbiome-service-to-advance-precision-care-for-women-and-children 2026-06-27T19:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/india-to-launch-aarogya-setu-2-0-and-national-drug-registry-in-major-digital-health-push 2026-06-27T17:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-to-launch-aarogya-setu-2-0-and-national-drug-registry-in-major-digital-health-push 2026-06-27T17:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-targeted-therapy-for-ultra-rare-kidney-disease-ic-mpgn-pegcetacoplan-shows-rapid-clinical-benefit 2026-06-27T17:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-targeted-therapy-for-ultra-rare-kidney-disease-ic-mpgn-pegcetacoplan-shows-rapid-clinical-benefit 2026-06-27T17:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/india-charts-path-to-precision-medicine-leadership-with-gene-therapy-genomics-and-ai-driven-healthcare 2026-06-27T17:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-charts-path-to-precision-medicine-leadership-with-gene-therapy-genomics-and-ai-driven-healthcare 2026-06-27T17:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/savara-cfo-exercises-options-as-company-approaches-pdufa-date-for-molbreevi-in-autoimmune-pulmonary-alveolar-proteinosis 2026-06-27T17:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/savara-cfo-exercises-options-as-company-approaches-pdufa-date-for-molbreevi-in-autoimmune-pulmonary-alveolar-proteinosis 2026-06-27T17:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-nine-in-10-nairobi-pharmacies-stocking-non-compliant-imported-medicines 2026-06-27T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-nine-in-10-nairobi-pharmacies-stocking-non-compliant-imported-medicines 2026-06-27T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/stockholm3-blood-test-detects-90-of-aggressive-prostate-cancers-outperforming-standard-psa-screening 2026-06-27T15:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stockholm3-blood-test-detects-90-of-aggressive-prostate-cancers-outperforming-standard-psa-screening 2026-06-27T15:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/severe-sunburns-permanently-increase-skin-cancer-risk-but-prevention-and-research-offer-hope 2026-06-27T15:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/severe-sunburns-permanently-increase-skin-cancer-risk-but-prevention-and-research-offer-hope 2026-06-27T15:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-variants-in-oxidative-stress-genes-explain-why-air-pollution-hits-some-asthma-patients-harder-than-others 2026-06-27T15:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-variants-in-oxidative-stress-genes-explain-why-air-pollution-hits-some-asthma-patients-harder-than-others 2026-06-27T15:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-trial-of-photoswitch-drug-shows-promise-for-restoring-vision-in-retinitis-pigmentosa 2026-06-27T15:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-trial-of-photoswitch-drug-shows-promise-for-restoring-vision-in-retinitis-pigmentosa 2026-06-27T15:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/atlanta-s-ebola-preparedness-tested-as-congo-team-arrives-for-world-cup-amid-deadly-outbreak 2026-06-27T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atlanta-s-ebola-preparedness-tested-as-congo-team-arrives-for-world-cup-amid-deadly-outbreak 2026-06-27T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-launches-x2-and-s2-series-centrifuges-with-natural-refrigerant-cooling-marking-industry-first-complete-portfolio 2026-06-27T11:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-launches-x2-and-s2-series-centrifuges-with-natural-refrigerant-cooling-marking-industry-first-complete-portfolio 2026-06-27T11:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/pennsylvania-confirms-two-measles-associated-deaths-first-in-35-years-as-outbreak-tops-393-cases 2026-06-27T09:10:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pennsylvania-confirms-two-measles-associated-deaths-first-in-35-years-as-outbreak-tops-393-cases 2026-06-27T09:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/home-blood-testing-devices-market-projected-to-reach-us-51-2-billion-by-2034-as-glucose-monitoring-dominates 2026-06-27T09:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/home-blood-testing-devices-market-projected-to-reach-us-51-2-billion-by-2034-as-glucose-monitoring-dominates 2026-06-27T09:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/states-intensify-legislative-push-to-regulate-pharmacy-benefit-managers-amid-rising-drug-cost-concerns 2026-06-27T08:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/states-intensify-legislative-push-to-regulate-pharmacy-benefit-managers-amid-rising-drug-cost-concerns 2026-06-27T08:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/neurocosmetics-the-emerging-science-of-skin-nervous-system-communication-in-dermatology 2026-06-27T08:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocosmetics-the-emerging-science-of-skin-nervous-system-communication-in-dermatology 2026-06-27T08:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-pipeline-review-btk-degraders-and-targeted-protein-degradation-advance-in-b-cell-malignancies 2026-06-27T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-pipeline-review-btk-degraders-and-targeted-protein-degradation-advance-in-b-cell-malignancies 2026-06-27T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-mandarin-trial-compares-therasphere-against-chemoembolization-in-chinese-liver-cancer-patients 2026-06-27T07:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-s-mandarin-trial-compares-therasphere-against-chemoembolization-in-chinese-liver-cancer-patients 2026-06-27T07:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-nurses-seek-s-2-4-million-for-baby-s-sma-gene-therapy-as-rare-disease-families-face-stark-realities 2026-06-27T06:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-nurses-seek-s-2-4-million-for-baby-s-sma-gene-therapy-as-rare-disease-families-face-stark-realities 2026-06-27T06:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/otraces-awarded-2-million-florida-grant-to-validate-proteomic-blood-test-for-reducing-unnecessary-prostate-biopsies 2026-06-27T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otraces-awarded-2-million-florida-grant-to-validate-proteomic-blood-test-for-reducing-unnecessary-prostate-biopsies 2026-06-27T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/brian-tsuji-takes-helm-at-cu-anschutz-skaggs-school-of-pharmacy-with-bold-top-five-vision 2026-06-27T03:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brian-tsuji-takes-helm-at-cu-anschutz-skaggs-school-of-pharmacy-with-bold-top-five-vision 2026-06-27T03:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/carilion-clinic-and-fbri-expand-theranostics-clinical-trials-positioning-southwest-virginia-as-a-hub-for-targeted-radiopharmaceutical-cancer-therapies 2026-06-27T02:10:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carilion-clinic-and-fbri-expand-theranostics-clinical-trials-positioning-southwest-virginia-as-a-hub-for-targeted-radiopharmaceutical-cancer-therapies 2026-06-27T02:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-and-lilly-back-ps85-million-obesity-pathway-innovation-programme-to-transform-care-across-12-regions 2026-06-27T02:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-government-and-lilly-back-ps85-million-obesity-pathway-innovation-programme-to-transform-care-across-12-regions 2026-06-27T02:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/jubilant-pharmova-secures-usfda-tentative-approval-for-pantoprazole-oral-suspension-eyes-2026-launch 2026-06-27T02:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jubilant-pharmova-secures-usfda-tentative-approval-for-pantoprazole-oral-suspension-eyes-2026-launch 2026-06-27T02:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/appili-therapeutics-reports-fy2026-results-highlights-us-40m-niaid-award-for-antifungal-vaccine-and-likmez-commercial-momentum 2026-06-27T00:10:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/appili-therapeutics-reports-fy2026-results-highlights-us-40m-niaid-award-for-antifungal-vaccine-and-likmez-commercial-momentum 2026-06-27T00:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/idsa-warns-new-acip-charter-changes-threaten-vaccine-access-and-public-trust 2026-06-27T00:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idsa-warns-new-acip-charter-changes-threaten-vaccine-access-and-public-trust 2026-06-27T00:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/keynote-966-long-term-follow-up-confirms-durable-survival-benefit-and-manageable-safety-of-pembrolizumab-chemoimmunotherapy 2026-06-27T00:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keynote-966-long-term-follow-up-confirms-durable-survival-benefit-and-manageable-safety-of-pembrolizumab-chemoimmunotherapy 2026-06-27T00:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/texas-a-m-researchers-develop-laser-technique-that-directly-measures-quantum-forces-driving-protein-interactions 2026-06-27T00:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-a-m-researchers-develop-laser-technique-that-directly-measures-quantum-forces-driving-protein-interactions 2026-06-27T00:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/uconn-school-of-pharmacy-renamed-to-school-of-pharmacy-and-pharmaceutical-sciences 2026-06-27T00:09:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uconn-school-of-pharmacy-renamed-to-school-of-pharmacy-and-pharmaceutical-sciences 2026-06-27T00:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/universe-pharmaceuticals-acquires-best-praise-international-for-10-75-million-to-expand-patent-portfolio-in-age-related-and-neurodegenerative-diseases 2026-06-27T00:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/universe-pharmaceuticals-acquires-best-praise-international-for-10-75-million-to-expand-patent-portfolio-in-age-related-and-neurodegenerative-diseases 2026-06-27T00:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-reports-107-revenue-growth-awaits-fda-decision-on-second-generation-lungfit-ph-system 2026-06-26T23:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-air-reports-107-revenue-growth-awaits-fda-decision-on-second-generation-lungfit-ph-system 2026-06-26T23:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/pennsylvania-hospital-inspection-reports-tracking-safety-compliance-at-chestnut-hill-and-paoli-hospitals 2026-06-26T23:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pennsylvania-hospital-inspection-reports-tracking-safety-compliance-at-chestnut-hill-and-paoli-hospitals 2026-06-26T23:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/snap-ceo-evan-spiegel-and-miranda-kerr-help-erase-550-million-in-medical-debt-for-over-261000-californians 2026-06-26T23:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/snap-ceo-evan-spiegel-and-miranda-kerr-help-erase-550-million-in-medical-debt-for-over-261000-californians 2026-06-26T23:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/california-legislature-passes-sb-936-to-restrict-nitrous-oxide-sales-amid-rising-recreational-abuse 2026-06-26T22:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-legislature-passes-sb-936-to-restrict-nitrous-oxide-sales-amid-rising-recreational-abuse 2026-06-26T22:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/li-fraumeni-syndrome-the-tp53-mutation-that-confers-nearly-100-lifetime-cancer-risk 2026-06-26T22:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/li-fraumeni-syndrome-the-tp53-mutation-that-confers-nearly-100-lifetime-cancer-risk 2026-06-26T22:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/csl-faces-dual-regulatory-headwinds-ema-recommends-tavneos-withdrawal-as-eu-opens-sanofi-flu-vaccine-probe 2026-06-26T22:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-faces-dual-regulatory-headwinds-ema-recommends-tavneos-withdrawal-as-eu-opens-sanofi-flu-vaccine-probe 2026-06-26T22:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/ai-therapy-chatbots-face-mounting-state-regulatory-scrutiny-as-pennsylvania-sues-character-ai-over-unauthorized-practice-of-medicine 2026-06-26T22:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-therapy-chatbots-face-mounting-state-regulatory-scrutiny-as-pennsylvania-sues-character-ai-over-unauthorized-practice-of-medicine 2026-06-26T22:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-lantheus-lnth-2501-pet-diagnostic-kit-citing-third-party-manufacturing-issues 2026-06-26T22:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-lantheus-lnth-2501-pet-diagnostic-kit-citing-third-party-manufacturing-issues 2026-06-26T22:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-guided-adjuvant-therapy-in-colorectal-cancer-bespoke-crc-and-the-promise-of-next-generation-drugs 2026-06-26T22:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-guided-adjuvant-therapy-in-colorectal-cancer-bespoke-crc-and-the-promise-of-next-generation-drugs 2026-06-26T22:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/himalaya-trial-tremelimumab-plus-durvalumab-establishes-new-frontline-standard-in-unresectable-hepatocellular-carcinoma 2026-06-26T22:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/himalaya-trial-tremelimumab-plus-durvalumab-establishes-new-frontline-standard-in-unresectable-hepatocellular-carcinoma 2026-06-26T22:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/generative-ai-clinical-decision-support-shows-safety-and-documentation-gains-but-no-significant-reduction-in-treatment-failure-in-kenyan-primary-care-trial 2026-06-26T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/generative-ai-clinical-decision-support-shows-safety-and-documentation-gains-but-no-significant-reduction-in-treatment-failure-in-kenyan-primary-care-trial 2026-06-26T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/mexico-cuts-clinical-trial-approval-times-from-120-to-30-days-unlocking-us-643-million-in-pharma-investment 2026-06-26T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mexico-cuts-clinical-trial-approval-times-from-120-to-30-days-unlocking-us-643-million-in-pharma-investment 2026-06-26T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-sobi-s-gout-therapy-nasp-citing-manufacturing-issues-only 2026-06-26T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-sobi-s-gout-therapy-nasp-citing-manufacturing-issues-only 2026-06-26T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-pasteur-secures-10-6-million-rise-pa-grant-to-decarbonize-swiftwater-vaccine-manufacturing-facility 2026-06-26T20:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-pasteur-secures-10-6-million-rise-pa-grant-to-decarbonize-swiftwater-vaccine-manufacturing-facility 2026-06-26T20:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/longevity-biomarkers-move-from-wellness-trend-to-precision-medicine-experts-chart-the-future-of-proactive-health 2026-06-26T20:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longevity-biomarkers-move-from-wellness-trend-to-precision-medicine-experts-chart-the-future-of-proactive-health 2026-06-26T20:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/india-proposes-elimination-of-import-license-requirement-for-preclinical-drug-testing-to-boost-r-d 2026-06-26T20:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-proposes-elimination-of-import-license-requirement-for-preclinical-drug-testing-to-boost-r-d 2026-06-26T20:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-pharma-faces-potential-us-section-301-trade-investigation-over-drug-pricing-policies 2026-06-26T20:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swiss-pharma-faces-potential-us-section-301-trade-investigation-over-drug-pricing-policies 2026-06-26T20:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-and-merck-s-personalized-cancer-vaccine-shows-positive-results-in-late-stage-trial 2026-06-26T19:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-and-merck-s-personalized-cancer-vaccine-shows-positive-results-in-late-stage-trial 2026-06-26T19:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/enhanced-games-parent-posts-60-million-loss-despite-billion-interaction-social-media-reach 2026-06-26T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhanced-games-parent-posts-60-million-loss-despite-billion-interaction-social-media-reach 2026-06-26T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/immersive-vr-with-synchronous-neurostimulation-outperforms-conventional-rehabilitation-in-chronic-stroke-trial 2026-06-26T18:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immersive-vr-with-synchronous-neurostimulation-outperforms-conventional-rehabilitation-in-chronic-stroke-trial 2026-06-26T18:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-identifies-novel-long-covid-biomarker-strengthening-rationale-for-hemopurifier-r-platform 2026-06-26T18:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aethlon-medical-identifies-novel-long-covid-biomarker-strengthening-rationale-for-hemopurifier-r-platform 2026-06-26T18:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-s-daybue-wins-eu-regulatory-backing-for-rett-syndrome-after-re-examination 2026-06-26T17:12:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-s-daybue-wins-eu-regulatory-backing-for-rett-syndrome-after-re-examination 2026-06-26T17:12:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-full-approval-to-laverdia-first-oral-at-home-treatment-for-canine-lymphoma 2026-06-26T17:11:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-full-approval-to-laverdia-first-oral-at-home-treatment-for-canine-lymphoma 2026-06-26T17:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/campbell-s-pharmacy-in-portrush-expands-clinical-services-with-robotic-dispensing-and-pharmacist-recruitment 2026-06-26T17:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/campbell-s-pharmacy-in-portrush-expands-clinical-services-with-robotic-dispensing-and-pharmacist-recruitment 2026-06-26T17:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/apda-survey-reveals-widespread-funding-disruptions-in-parkinson-s-research-prompting-bridge-funding-program 2026-06-26T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apda-survey-reveals-widespread-funding-disruptions-in-parkinson-s-research-prompting-bridge-funding-program 2026-06-26T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/zelluna-closes-uv1-cancer-vaccine-programme-after-fifth-phase-ii-trial-failure-in-ovarian-cancer 2026-06-26T17:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zelluna-closes-uv1-cancer-vaccine-programme-after-fifth-phase-ii-trial-failure-in-ovarian-cancer 2026-06-26T17:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-altered-smell-and-taste-in-type-2-diabetes-patients-large-scale-analysis-finds 2026-06-26T17:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-altered-smell-and-taste-in-type-2-diabetes-patients-large-scale-analysis-finds 2026-06-26T17:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/spermidine-supplement-shows-promise-in-boosting-covid-19-vaccine-response-in-older-adults 2026-06-26T17:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spermidine-supplement-shows-promise-in-boosting-covid-19-vaccine-response-in-older-adults 2026-06-26T17:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/china-overhauls-cosmetic-new-ingredient-regulations-to-spur-innovation-and-reduce-industry-burden 2026-06-26T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-overhauls-cosmetic-new-ingredient-regulations-to-spur-innovation-and-reduce-industry-burden 2026-06-26T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/costco-and-scan-group-partner-to-launch-costco-branded-medicare-advantage-plan 2026-06-26T16:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/costco-and-scan-group-partner-to-launch-costco-branded-medicare-advantage-plan 2026-06-26T16:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-rejects-omeros-narsoplimab-for-stem-cell-transplant-complication-citing-insufficient-efficacy-data 2026-06-26T16:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-rejects-omeros-narsoplimab-for-stem-cell-transplant-complication-citing-insufficient-efficacy-data 2026-06-26T16:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/epigenetic-editing-enters-the-clinic-first-trial-data-and-a-pipeline-poised-to-redefine-gene-therapy 2026-06-26T16:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epigenetic-editing-enters-the-clinic-first-trial-data-and-a-pipeline-poised-to-redefine-gene-therapy 2026-06-26T16:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/curis-opens-eleven-clinical-sites-for-phase-2-takeaim-cll-study-of-emavusertib-zanubrutinib-combination 2026-06-26T15:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curis-opens-eleven-clinical-sites-for-phase-2-takeaim-cll-study-of-emavusertib-zanubrutinib-combination 2026-06-26T15:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/four-years-after-dobbs-abortion-numbers-surpass-pre-roe-levels-as-public-opinion-undergoes-historic-realignment 2026-06-26T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-years-after-dobbs-abortion-numbers-surpass-pre-roe-levels-as-public-opinion-undergoes-historic-realignment 2026-06-26T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/pioneering-crispr-gene-therapy-for-ctla-4-insufficiency-advances-toward-first-in-human-trial 2026-06-26T13:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pioneering-crispr-gene-therapy-for-ctla-4-insufficiency-advances-toward-first-in-human-trial 2026-06-26T13:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/elixirgen-therapeutics-and-nippon-shinyaku-enter-option-agreement-for-full-length-dystrophin-mrna-therapy-exg-7001-in-duchenne-muscular-dystrophy 2026-06-26T13:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elixirgen-therapeutics-and-nippon-shinyaku-enter-option-agreement-for-full-length-dystrophin-mrna-therapy-exg-7001-in-duchenne-muscular-dystrophy 2026-06-26T13:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/network-medicine-framework-identifies-existing-drugs-that-could-be-repurposed-to-target-hallmarks-of-aging 2026-06-26T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/network-medicine-framework-identifies-existing-drugs-that-could-be-repurposed-to-target-hallmarks-of-aging 2026-06-26T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/smart-nanoplatform-uses-wound-acidity-to-trigger-accelerated-healing 2026-06-26T11:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-nanoplatform-uses-wound-acidity-to-trigger-accelerated-healing 2026-06-26T11:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarcopenia-identified-as-key-predictor-of-immunotherapy-outcomes-in-advanced-nsclc 2026-06-26T06:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarcopenia-identified-as-key-predictor-of-immunotherapy-outcomes-in-advanced-nsclc 2026-06-26T06:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/foley-hoag-announces-cell-gene-therapy-summit-2026 2026-06-26T05:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foley-hoag-announces-cell-gene-therapy-summit-2026 2026-06-26T05:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/precigen-cfo-sells-1-1-million-in-shares-amid-stock-surge-and-fda-orphan-drug-designation-for-papzimeos 2026-06-26T05:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precigen-cfo-sells-1-1-million-in-shares-amid-stock-surge-and-fda-orphan-drug-designation-for-papzimeos 2026-06-26T05:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-charts-path-to-top-5-oncology-company-through-adc-and-car-t-expansion 2026-06-26T03:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-charts-path-to-top-5-oncology-company-through-adc-and-car-t-expansion 2026-06-26T03:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-lerochol-bla-accepted-by-china-nmpa-for-hypercholesterolemia 2026-06-26T03:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-lerochol-bla-accepted-by-china-nmpa-for-hypercholesterolemia 2026-06-26T03:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/marquis-who-s-who-recognizes-shawn-patrick-o-brien-for-four-decades-of-pharmaceutical-leadership 2026-06-26T03:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marquis-who-s-who-recognizes-shawn-patrick-o-brien-for-four-decades-of-pharmaceutical-leadership 2026-06-26T03:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-india-reports-16-6-profit-rise-in-q1fy26-driven-by-revenue-growth-and-margin-expansion 2026-06-26T03:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-india-reports-16-6-profit-rise-in-q1fy26-driven-by-revenue-growth-and-margin-expansion 2026-06-26T03:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/first-commercially-sponsored-clinical-trial-in-regional-western-australia-targets-chemotherapy-induced-nausea 2026-06-26T00:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-commercially-sponsored-clinical-trial-in-regional-western-australia-targets-chemotherapy-induced-nausea 2026-06-26T00:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/medical-ai-models-expose-rare-disease-and-minority-patients-to-privacy-attacks-nature-study-warns 2026-06-26T00:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-ai-models-expose-rare-disease-and-minority-patients-to-privacy-attacks-nature-study-warns 2026-06-26T00:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/vorasidenib-offers-targeted-treatment-for-idh-mutant-low-grade-gliomas 2026-06-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vorasidenib-offers-targeted-treatment-for-idh-mutant-low-grade-gliomas 2026-06-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/larimar-therapeutics-faces-securities-investigation-after-anaphylaxis-safety-signal-emerges-in-nomlabofusp-trials-for-friedreich-s-ataxia 2026-06-25T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/larimar-therapeutics-faces-securities-investigation-after-anaphylaxis-safety-signal-emerges-in-nomlabofusp-trials-for-friedreich-s-ataxia 2026-06-25T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/nrx-pharmaceuticals-and-kadima-neuropsychiatry-institute-clash-over-failed-acquisition-arbitration-and-scientific-direction 2026-06-25T22:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-and-kadima-neuropsychiatry-institute-clash-over-failed-acquisition-arbitration-and-scientific-direction 2026-06-25T22:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-whole-genome-sequencing-cuts-severe-neonatal-rare-disease-diagnosis-from-5-years-to-5-5-days 2026-06-25T22:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapid-whole-genome-sequencing-cuts-severe-neonatal-rare-disease-diagnosis-from-5-years-to-5-5-days 2026-06-25T22:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/how-a-bacterial-survival-strategy-is-changing-medicine-baylor-team-uncovers-antibiotic-persistence-mechanism 2026-06-25T22:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-a-bacterial-survival-strategy-is-changing-medicine-baylor-team-uncovers-antibiotic-persistence-mechanism 2026-06-25T22:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/medication-adherence-in-copd-cost-barriers-and-strategies-for-affordability-on-fixed-incomes 2026-06-25T21:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medication-adherence-in-copd-cost-barriers-and-strategies-for-affordability-on-fixed-incomes 2026-06-25T21:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/experts-call-for-who-to-recognize-ocular-toxoplasmosis-as-a-neglected-tropical-disease 2026-06-25T21:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-call-for-who-to-recognize-ocular-toxoplasmosis-as-a-neglected-tropical-disease 2026-06-25T21:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/updoc-debuts-first-fda-cleared-agentic-clinical-ai-platform-for-real-time-patient-care 2026-06-25T21:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updoc-debuts-first-fda-cleared-agentic-clinical-ai-platform-for-real-time-patient-care 2026-06-25T21:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-proposes-33-4-cut-to-hospital-reimbursement-for-340b-drugs-sparking-safety-net-hospital-backlash 2026-06-25T21:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-proposes-33-4-cut-to-hospital-reimbursement-for-340b-drugs-sparking-safety-net-hospital-backlash 2026-06-25T21:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/updated-nccn-guidelines-expand-mental-health-screening-to-improve-cancer-survivorship-care 2026-06-25T21:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-nccn-guidelines-expand-mental-health-screening-to-improve-cancer-survivorship-care 2026-06-25T21:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/texas-appeals-court-signals-j-j-and-kenvue-may-be-dismissed-from-tylenol-autism-lawsuit 2026-06-25T21:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-appeals-court-signals-j-j-and-kenvue-may-be-dismissed-from-tylenol-autism-lawsuit 2026-06-25T21:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-team-awarded-7-49-million-cirm-grant-to-develop-off-the-shelf-car-nkt-cell-therapy-for-multiple-sclerosis 2026-06-25T20:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-team-awarded-7-49-million-cirm-grant-to-develop-off-the-shelf-car-nkt-cell-therapy-for-multiple-sclerosis 2026-06-25T20:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-321589-to-rowan-university-for-parkinson-s-disease-research-on-aerodigestive-dysfunction 2026-06-25T19:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-321589-to-rowan-university-for-parkinson-s-disease-research-on-aerodigestive-dysfunction 2026-06-25T19:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-increased-risk-of-smell-and-taste-disturbances-study-finds 2026-06-25T19:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-increased-risk-of-smell-and-taste-disturbances-study-finds 2026-06-25T19:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/trem-1-emerges-as-master-amplifier-of-inflammation-offering-new-therapeutic-avenue-for-sepsis-arthritis-and-neurodegenerative-diseases 2026-06-25T19:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trem-1-emerges-as-master-amplifier-of-inflammation-offering-new-therapeutic-avenue-for-sepsis-arthritis-and-neurodegenerative-diseases 2026-06-25T19:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/onco-doac-bleed-score-new-risk-stratification-tool-for-bleeding-risk-in-cancer-associated-vte-patients-on-doacs 2026-06-25T19:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-doac-bleed-score-new-risk-stratification-tool-for-bleeding-risk-in-cancer-associated-vte-patients-on-doacs 2026-06-25T19:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/could-a-simple-breath-test-detect-diabetes-before-symptoms-appear 2026-06-25T19:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/could-a-simple-breath-test-detect-diabetes-before-symptoms-appear 2026-06-25T19:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/attunio-health-expands-ai-powered-precision-psychiatry-platform-with-quest-diagnostics-and-getlabs 2026-06-25T19:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/attunio-health-expands-ai-powered-precision-psychiatry-platform-with-quest-diagnostics-and-getlabs 2026-06-25T19:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/imcd-opens-state-of-the-art-pharmaceutical-technical-centre-in-new-jersey 2026-06-25T18:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imcd-opens-state-of-the-art-pharmaceutical-technical-centre-in-new-jersey 2026-06-25T18:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/patient-portal-messaging-surges-153-since-2020-reshaping-us-healthcare-delivery 2026-06-25T18:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-portal-messaging-surges-153-since-2020-reshaping-us-healthcare-delivery 2026-06-25T18:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/abo-101-gene-editing-therapy-for-primary-hyperoxaluria-type-1-granted-orphan-drug-designation-by-european-commission 2026-06-25T18:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abo-101-gene-editing-therapy-for-primary-hyperoxaluria-type-1-granted-orphan-drug-designation-by-european-commission 2026-06-25T18:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/prostate-cancer-cases-rising-3-annually-as-experts-renew-debate-over-psa-screening 2026-06-25T17:11:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prostate-cancer-cases-rising-3-annually-as-experts-renew-debate-over-psa-screening 2026-06-25T17:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-launch-prices-for-new-drugs-fell-in-2025-as-fewer-costly-gene-therapies-reached-market 2026-06-25T17:11:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-launch-prices-for-new-drugs-fell-in-2025-as-fewer-costly-gene-therapies-reached-market 2026-06-25T17:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/chan-zuckerberg-biohub-opens-fourth-rare-as-one-funding-round-expands-ai-powered-drug-repurposing-partnership-with-every-cure 2026-06-25T17:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chan-zuckerberg-biohub-opens-fourth-rare-as-one-funding-round-expands-ai-powered-drug-repurposing-partnership-with-every-cure 2026-06-25T17:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/global-proteins-protein-crystals-market-projected-to-reach-960-billion-by-2030-driven-by-biopharmaceutical-r-d-and-structural-biology-advances 2026-06-25T17:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-proteins-protein-crystals-market-projected-to-reach-960-billion-by-2030-driven-by-biopharmaceutical-r-d-and-structural-biology-advances 2026-06-25T17:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/aston-university-leads-eur1-2m-european-project-to-develop-living-magnetobots-for-targeted-cancer-theranostics 2026-06-25T17:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aston-university-leads-eur1-2m-european-project-to-develop-living-magnetobots-for-targeted-cancer-theranostics 2026-06-25T17:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/legacy-ultrasound-cybersecurity-framework-90-of-cleared-systems-predate-us-cyber-device-statute 2026-06-25T17:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legacy-ultrasound-cybersecurity-framework-90-of-cleared-systems-predate-us-cyber-device-statute 2026-06-25T17:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/vaccine-adjuvants-market-projected-to-reach-usd-6-19-billion-by-2035-driven-by-mrna-and-oncology-vaccine-innovation 2026-06-25T17:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaccine-adjuvants-market-projected-to-reach-usd-6-19-billion-by-2035-driven-by-mrna-and-oncology-vaccine-innovation 2026-06-25T17:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/aidoc-receives-fda-breakthrough-device-designation-for-ai-that-drafts-radiology-reports 2026-06-25T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aidoc-receives-fda-breakthrough-device-designation-for-ai-that-drafts-radiology-reports 2026-06-25T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/biomarkers-reveal-immune-overactivity-not-exhaustion-drives-chronic-critical-illness-in-trauma-patients 2026-06-25T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarkers-reveal-immune-overactivity-not-exhaustion-drives-chronic-critical-illness-in-trauma-patients 2026-06-25T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/nanomedicine-strategies-for-remodeling-the-solid-tumor-microenvironment-stromal-targeting-hypoxia-modulation-and-photodynamic-immunotherapy 2026-06-25T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanomedicine-strategies-for-remodeling-the-solid-tumor-microenvironment-stromal-targeting-hypoxia-modulation-and-photodynamic-immunotherapy 2026-06-25T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/planned-parenthood-to-reopen-in-new-orleans-with-non-abortion-health-services-marking-partial-return-to-louisiana 2026-06-25T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/planned-parenthood-to-reopen-in-new-orleans-with-non-abortion-health-services-marking-partial-return-to-louisiana 2026-06-25T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/navi-teen-co-designed-digital-wellness-app-launches-statewide-in-new-mexico-to-address-youth-mental-health-crisis 2026-06-25T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navi-teen-co-designed-digital-wellness-app-launches-statewide-in-new-mexico-to-address-youth-mental-health-crisis 2026-06-25T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/novakand-pharma-pivots-to-orphan-drug-development-for-treatment-resistant-ovarian-cancer-and-leukemia 2026-06-25T16:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novakand-pharma-pivots-to-orphan-drug-development-for-treatment-resistant-ovarian-cancer-and-leukemia 2026-06-25T16:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/asco-living-guideline-adds-repotrectinib-and-zongertinib-for-advanced-nsclc-with-driver-alterations 2026-06-25T16:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-living-guideline-adds-repotrectinib-and-zongertinib-for-advanced-nsclc-with-driver-alterations 2026-06-25T16:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/evaluate-s-ask-ella-wins-enterprise-ai-search-solution-of-the-year-at-2026-ai-breakthrough-awards 2026-06-25T16:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaluate-s-ask-ella-wins-enterprise-ai-search-solution-of-the-year-at-2026-ai-breakthrough-awards 2026-06-25T16:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/ai-is-reshaping-how-doctors-train-and-what-they-become 2026-06-25T16:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-is-reshaping-how-doctors-train-and-what-they-become 2026-06-25T16:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/vhio-renews-severo-ochoa-centre-of-excellence-accreditation-with-near-perfect-score 2026-06-25T15:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vhio-renews-severo-ochoa-centre-of-excellence-accreditation-with-near-perfect-score 2026-06-25T15:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-boom-creates-tissue-restoration-gap-as-conexeu-advances-regenerative-platform-toward-2027-fda-submission 2026-06-25T15:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-weight-loss-boom-creates-tissue-restoration-gap-as-conexeu-advances-regenerative-platform-toward-2027-fda-submission 2026-06-25T15:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/eu-funds-first-randomized-phage-therapy-trial-with-eur15-million-to-combat-recurrent-utis 2026-06-25T15:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-funds-first-randomized-phage-therapy-trial-with-eur15-million-to-combat-recurrent-utis 2026-06-25T15:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/massive-plasma-metabolite-atlas-maps-blood-chemistry-to-hundreds-of-diseases-in-390000-individuals 2026-06-25T15:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massive-plasma-metabolite-atlas-maps-blood-chemistry-to-hundreds-of-diseases-in-390000-individuals 2026-06-25T15:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/drug-repurposing-screen-identifies-70-existing-compounds-including-beta-lactam-antibiotics-that-block-deadly-hantavirus-infections 2026-06-25T15:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-repurposing-screen-identifies-70-existing-compounds-including-beta-lactam-antibiotics-that-block-deadly-hantavirus-infections 2026-06-25T15:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-real-world-data-are-turning-the-promise-of-precision-medicine-into-clinical-reality 2026-06-25T15:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-real-world-data-are-turning-the-promise-of-precision-medicine-into-clinical-reality 2026-06-25T15:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/aecc-awards-eur7-35-million-to-61-madrid-cancer-research-projects-cnio-secures-over-eur3-million 2026-06-25T15:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aecc-awards-eur7-35-million-to-61-madrid-cancer-research-projects-cnio-secures-over-eur3-million 2026-06-25T15:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/kite-and-american-cancer-society-renew-partnership-to-close-car-t-cell-therapy-access-gap-for-blood-cancer-patients 2026-06-25T15:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kite-and-american-cancer-society-renew-partnership-to-close-car-t-cell-therapy-access-gap-for-blood-cancer-patients 2026-06-25T15:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/greenstone-biosciences-awarded-breakthrough-t1d-grant-to-build-a-t1d-derived-islet-cell-platform 2026-06-25T15:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenstone-biosciences-awarded-breakthrough-t1d-grant-to-build-a-t1d-derived-islet-cell-platform 2026-06-25T15:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/new-national-recommendations-and-nice-quality-standard-aim-to-transform-rare-disease-care 2026-06-25T14:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-national-recommendations-and-nice-quality-standard-aim-to-transform-rare-disease-care 2026-06-25T14:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/cord-blood-biomarkers-show-promise-for-early-risk-stratification-in-neonatal-encephalopathy-meta-analysis-finds 2026-06-25T13:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cord-blood-biomarkers-show-promise-for-early-risk-stratification-in-neonatal-encephalopathy-meta-analysis-finds 2026-06-25T13:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/germany-s-merck-kgaa-to-acquire-bio-techne-in-11-3-billion-life-sciences-mega-deal 2026-06-25T13:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/germany-s-merck-kgaa-to-acquire-bio-techne-in-11-3-billion-life-sciences-mega-deal 2026-06-25T13:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/rewiring-car-t-cell-signaling-plat-chimeric-switch-converts-pd-1-inhibition-into-t-cell-activation 2026-06-25T13:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rewiring-car-t-cell-signaling-plat-chimeric-switch-converts-pd-1-inhibition-into-t-cell-activation 2026-06-25T13:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/shaanxi-micot-advances-first-in-class-dual-target-anticoagulant-mt1002-into-phase-ii-hemodialysis-trial 2026-06-25T13:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shaanxi-micot-advances-first-in-class-dual-target-anticoagulant-mt1002-into-phase-ii-hemodialysis-trial 2026-06-25T13:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/minaris-and-bionova-scientific-partner-to-expand-plasmid-dna-supply-for-cell-and-gene-therapy-manufacturing 2026-06-25T13:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minaris-and-bionova-scientific-partner-to-expand-plasmid-dna-supply-for-cell-and-gene-therapy-manufacturing 2026-06-25T13:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/racura-oncology-doses-first-patient-in-phase-1-harness-1-trial-of-rc220-for-egfr-mutant-nsclc 2026-06-25T13:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racura-oncology-doses-first-patient-in-phase-1-harness-1-trial-of-rc220-for-egfr-mutant-nsclc 2026-06-25T13:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/cstone-strikes-oceania-deal-with-arrotex-for-anti-pd-l1-antibody-sugemalimab 2026-06-25T13:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cstone-strikes-oceania-deal-with-arrotex-for-anti-pd-l1-antibody-sugemalimab 2026-06-25T13:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/global-bone-densitometers-market-to-reach-usd-584-8-million-by-2036-driven-by-value-based-care-and-enterprise-imaging-integration 2026-06-25T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-bone-densitometers-market-to-reach-usd-584-8-million-by-2036-driven-by-value-based-care-and-enterprise-imaging-integration 2026-06-25T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-geroprotective-probiotic-and-its-functional-metabolite-counteract-inflammaging-to-extend-healthspan 2026-06-25T12:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-geroprotective-probiotic-and-its-functional-metabolite-counteract-inflammaging-to-extend-healthspan 2026-06-25T12:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/embarc-and-insmed-announce-landmark-3000-patient-study-to-evaluate-whether-brensocatib-can-modify-the-course-of-bronchiectasis 2026-06-25T12:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/embarc-and-insmed-announce-landmark-3000-patient-study-to-evaluate-whether-brensocatib-can-modify-the-course-of-bronchiectasis 2026-06-25T12:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/c-ray-therapeutics-secures-radiopharmaceutical-production-license-in-china-bolstering-crdmo-capabilities 2026-06-25T12:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-ray-therapeutics-secures-radiopharmaceutical-production-license-in-china-bolstering-crdmo-capabilities 2026-06-25T12:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/decentralised-trials-in-apac-why-the-frontier-hasn-t-arrived-and-what-it-will-take 2026-06-25T11:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/decentralised-trials-in-apac-why-the-frontier-hasn-t-arrived-and-what-it-will-take 2026-06-25T11:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/civicascript-s-nonprofit-model-delivers-16-million-in-generic-drug-savings-in-2025-cumulative-savings-reach-44-million 2026-06-25T11:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/civicascript-s-nonprofit-model-delivers-16-million-in-generic-drug-savings-in-2025-cumulative-savings-reach-44-million 2026-06-25T11:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/western-nevada-college-students-advance-biomedical-research-through-nih-funded-inbre-program 2026-06-25T11:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/western-nevada-college-students-advance-biomedical-research-through-nih-funded-inbre-program 2026-06-25T11:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/mesoblast-draws-us-50-million-from-five-year-non-dilutive-facility-to-strengthen-balance-sheet-and-retire-high-cost-debt 2026-06-25T11:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mesoblast-draws-us-50-million-from-five-year-non-dilutive-facility-to-strengthen-balance-sheet-and-retire-high-cost-debt 2026-06-25T11:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/sujini-ponnusamy-pioneering-the-convergence-of-ai-and-genomics-in-precision-oncology 2026-06-25T11:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sujini-ponnusamy-pioneering-the-convergence-of-ai-and-genomics-in-precision-oncology 2026-06-25T11:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/how-peacemaker-immune-cells-could-unlock-long-term-disease-remission-across-autoimmunity-and-beyond 2026-06-25T11:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-peacemaker-immune-cells-could-unlock-long-term-disease-remission-across-autoimmunity-and-beyond 2026-06-25T11:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/proposed-federal-rule-threatens-to-politicize-nih-grantmaking-sparking-bipartisan-alarm-in-biomedical-research-community 2026-06-25T11:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proposed-federal-rule-threatens-to-politicize-nih-grantmaking-sparking-bipartisan-alarm-in-biomedical-research-community 2026-06-25T11:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/college-students-in-mental-health-crisis-are-increasingly-turning-to-unregulated-ai-for-support-study-finds 2026-06-25T09:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/college-students-in-mental-health-crisis-are-increasingly-turning-to-unregulated-ai-for-support-study-finds 2026-06-25T09:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/crism-therapeutics-advances-toward-patient-recruitment-for-phase-ii-glioblastoma-trial-of-irinotecan-chemoseed 2026-06-25T08:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crism-therapeutics-advances-toward-patient-recruitment-for-phase-ii-glioblastoma-trial-of-irinotecan-chemoseed 2026-06-25T08:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-molecules-doses-first-patient-in-phase-2a-trial-of-helicase-primase-inhibitor-adibelivir-for-recurrent-genital-herpes 2026-06-25T08:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-molecules-doses-first-patient-in-phase-2a-trial-of-helicase-primase-inhibitor-adibelivir-for-recurrent-genital-herpes 2026-06-25T08:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/the-splice-of-life-how-alternative-splicing-is-reshaping-the-therapeutic-landscape-across-rare-diseases-and-oncology 2026-06-25T08:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-splice-of-life-how-alternative-splicing-is-reshaping-the-therapeutic-landscape-across-rare-diseases-and-oncology 2026-06-25T08:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-poised-to-cross-100-billion-revenue-milestone-amid-patent-cliff-navigation 2026-06-25T08:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-poised-to-cross-100-billion-revenue-milestone-amid-patent-cliff-navigation 2026-06-25T08:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/choroidal-medium-large-vascular-index-identified-as-optimal-oct-a-biomarker-for-thyroid-eye-disease-activity 2026-06-25T08:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/choroidal-medium-large-vascular-index-identified-as-optimal-oct-a-biomarker-for-thyroid-eye-disease-activity 2026-06-25T08:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-opens-first-asia-pacific-base-in-hong-kong-as-chinese-biotech-out-licensing-deals-surge 2026-06-25T06:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royalty-pharma-opens-first-asia-pacific-base-in-hong-kong-as-chinese-biotech-out-licensing-deals-surge 2026-06-25T06:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/liposomal-nanoparticulate-drug-delivery-systems-engineering-membrane-destabilization-for-precision-nanomedicine 2026-06-25T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liposomal-nanoparticulate-drug-delivery-systems-engineering-membrane-destabilization-for-precision-nanomedicine 2026-06-25T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-mexico-governor-demands-criminal-probe-of-dea-over-fentanyl-shipments-allowed-to-reach-streets 2026-06-25T05:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-mexico-governor-demands-criminal-probe-of-dea-over-fentanyl-shipments-allowed-to-reach-streets 2026-06-25T05:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/hydrogels-in-autoimmune-disease-from-passive-carriers-to-active-immune-regulation-platforms 2026-06-25T05:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydrogels-in-autoimmune-disease-from-passive-carriers-to-active-immune-regulation-platforms 2026-06-25T05:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/policy-talent-and-innovation-are-fueling-pennsylvania-s-life-sciences-growth 2026-06-25T04:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/policy-talent-and-innovation-are-fueling-pennsylvania-s-life-sciences-growth 2026-06-25T04:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/shapiro-administration-proposes-900000-food-is-medicine-pilot-to-provide-medically-tailored-meals-for-medicaid-recipients 2026-06-25T03:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shapiro-administration-proposes-900000-food-is-medicine-pilot-to-provide-medically-tailored-meals-for-medicaid-recipients 2026-06-25T03:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-testing-expansion-poised-to-dramatically-increase-demand-for-als-specialist-care-across-the-united-states 2026-06-25T02:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-testing-expansion-poised-to-dramatically-increase-demand-for-als-specialist-care-across-the-united-states 2026-06-25T02:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/heavy-alcohol-use-may-accelerate-brain-aging-and-alzheimer-s-pathology-through-distinct-biological-mechanisms-animal-studies-suggest 2026-06-25T01:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heavy-alcohol-use-may-accelerate-brain-aging-and-alzheimer-s-pathology-through-distinct-biological-mechanisms-animal-studies-suggest 2026-06-25T01:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-launches-multidisciplinary-initiative-to-advance-igg4-related-disease-diagnosis-research-and-care 2026-06-25T01:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-launches-multidisciplinary-initiative-to-advance-igg4-related-disease-diagnosis-research-and-care 2026-06-25T01:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-testing-in-reproductive-medicine-advancing-diagnosis-of-male-and-female-infertility 2026-06-25T01:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-testing-in-reproductive-medicine-advancing-diagnosis-of-male-and-female-infertility 2026-06-25T01:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/ghrelin-receptor-agonist-ac01-shows-safety-and-hemodynamic-promise-in-early-heart-failure-trial 2026-06-25T00:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ghrelin-receptor-agonist-ac01-shows-safety-and-hemodynamic-promise-in-early-heart-failure-trial 2026-06-25T00:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/epicrispr-s-epi-321-reaches-full-enrolment-in-first-in-human-epigenetic-crispr-therapy-trial 2026-06-25T00:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epicrispr-s-epi-321-reaches-full-enrolment-in-first-in-human-epigenetic-crispr-therapy-trial 2026-06-25T00:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/prescient-s-first-in-class-ggtase-1-inhibitor-ptx-100-accelerates-toward-pivotal-phase-2-milestones-in-ctcl 2026-06-25T00:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prescient-s-first-in-class-ggtase-1-inhibitor-ptx-100-accelerates-toward-pivotal-phase-2-milestones-in-ctcl 2026-06-25T00:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/telehealth-platforms-launch-structured-virtual-tirzepatide-assessment-programs-for-weight-management 2026-06-25T00:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telehealth-platforms-launch-structured-virtual-tirzepatide-assessment-programs-for-weight-management 2026-06-25T00:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/dr-christina-rahm-and-drc-ventures-win-gold-stevie-award-for-patent-driven-manufacturing-innovation 2026-06-24T23:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-christina-rahm-and-drc-ventures-win-gold-stevie-award-for-patent-driven-manufacturing-innovation 2026-06-24T23:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/radioligand-therapy-a-30-billion-cancer-breakthrough-faces-geopolitical-headwinds 2026-06-24T23:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radioligand-therapy-a-30-billion-cancer-breakthrough-faces-geopolitical-headwinds 2026-06-24T23:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/exozymes-secures-2-million-nih-grant-to-advance-cannabinoid-analogs-for-drug-discovery 2026-06-24T22:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exozymes-secures-2-million-nih-grant-to-advance-cannabinoid-analogs-for-drug-discovery 2026-06-24T22:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-patents-and-africa-the-covid-19-lessons-we-still-have-not-learned 2026-06-24T22:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-patents-and-africa-the-covid-19-lessons-we-still-have-not-learned 2026-06-24T22:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/calcimedica-s-auxora-clears-fda-safety-review-kourage-trial-in-aki-to-resume-dosing 2026-06-24T22:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calcimedica-s-auxora-clears-fda-safety-review-kourage-trial-in-aki-to-resume-dosing 2026-06-24T22:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/department-of-health-abu-dhabi-and-children-s-hospital-of-philadelphia-launch-strategic-collaboration-to-advance-gene-editing-for-rare-diseases 2026-06-24T22:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/department-of-health-abu-dhabi-and-children-s-hospital-of-philadelphia-launch-strategic-collaboration-to-advance-gene-editing-for-rare-diseases 2026-06-24T22:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/tobacco-free-nicotine-products-why-tobacco-free-does-not-mean-risk-free 2026-06-24T22:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tobacco-free-nicotine-products-why-tobacco-free-does-not-mean-risk-free 2026-06-24T22:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/botanicure-s-botanical-drug-bota-ns1-shows-early-promise-for-cognitive-decline-in-pilot-study 2026-06-24T21:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/botanicure-s-botanical-drug-bota-ns1-shows-early-promise-for-cognitive-decline-in-pilot-study 2026-06-24T21:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-declares-0-43-third-quarter-2026-dividend-marking-351st-consecutive-quarterly-payout 2026-06-24T21:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-declares-0-43-third-quarter-2026-dividend-marking-351st-consecutive-quarterly-payout 2026-06-24T21:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/houston-methodist-receives-110-million-donation-largest-in-health-system-s-107-year-history 2026-06-24T21:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/houston-methodist-receives-110-million-donation-largest-in-health-system-s-107-year-history 2026-06-24T21:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-patients-and-advocacy-groups-escalate-pressure-to-fund-ovarian-cancer-drug-elahere-after-negotiations-collapse 2026-06-24T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-patients-and-advocacy-groups-escalate-pressure-to-fund-ovarian-cancer-drug-elahere-after-negotiations-collapse 2026-06-24T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/msu-researchers-uncover-how-ovarian-cancer-resists-chemotherapy-and-how-to-reverse-it 2026-06-24T21:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msu-researchers-uncover-how-ovarian-cancer-resists-chemotherapy-and-how-to-reverse-it 2026-06-24T21:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/how-decentralized-clinical-trials-are-reshaping-patient-recruitment-and-advancing-health-equity 2026-06-24T21:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-decentralized-clinical-trials-are-reshaping-patient-recruitment-and-advancing-health-equity 2026-06-24T21:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-global-genomic-equity-the-case-for-national-genome-projects-in-africa 2026-06-24T20:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-global-genomic-equity-the-case-for-national-genome-projects-in-africa 2026-06-24T20:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/yale-study-reveals-gut-based-iga-immunity-as-key-to-future-norovirus-vaccines-and-treatments 2026-06-24T20:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-study-reveals-gut-based-iga-immunity-as-key-to-future-norovirus-vaccines-and-treatments 2026-06-24T20:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/chop-researchers-develop-nanoparticle-platform-to-accelerate-cancer-immunotherapy-screening 2026-06-24T19:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chop-researchers-develop-nanoparticle-platform-to-accelerate-cancer-immunotherapy-screening 2026-06-24T19:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/rare-histological-subtypes-of-triple-negative-breast-cancer-a-comprehensive-review-highlights-diagnostic-and-therapeutic-implications 2026-06-24T19:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rare-histological-subtypes-of-triple-negative-breast-cancer-a-comprehensive-review-highlights-diagnostic-and-therapeutic-implications 2026-06-24T19:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/jane-coffin-childs-fund-names-32-postdoctoral-fellows-for-2026-committing-nearly-9-million-to-early-career-biomedical-research 2026-06-24T19:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jane-coffin-childs-fund-names-32-postdoctoral-fellows-for-2026-committing-nearly-9-million-to-early-career-biomedical-research 2026-06-24T19:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/dea-to-present-testimony-on-medical-marijuana-benefits-in-rescheduling-hearing-as-opponents-push-harms-narrative 2026-06-24T19:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-to-present-testimony-on-medical-marijuana-benefits-in-rescheduling-hearing-as-opponents-push-harms-narrative 2026-06-24T19:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/boron-based-nanostructure-delivers-sugars-directly-into-cells-without-toxic-solvents 2026-06-24T18:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boron-based-nanostructure-delivers-sugars-directly-into-cells-without-toxic-solvents 2026-06-24T18:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/laboratory-beagles-may-bridge-the-autism-drug-discovery-gap-new-perspective-argues 2026-06-24T18:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laboratory-beagles-may-bridge-the-autism-drug-discovery-gap-new-perspective-argues 2026-06-24T18:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-part-a-trust-fund-depletion-projected-for-q2-2033-one-quarter-earlier-than-prior-estimate 2026-06-24T18:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-part-a-trust-fund-depletion-projected-for-q2-2033-one-quarter-earlier-than-prior-estimate 2026-06-24T18:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/v-synthes2-enables-physics-based-virtual-screening-of-36-billion-compounds-for-challenging-drug-targets 2026-06-24T18:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/v-synthes2-enables-physics-based-virtual-screening-of-36-billion-compounds-for-challenging-drug-targets 2026-06-24T18:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/sponsors-urged-to-drop-qes-everywhere-default-in-global-trials-adopt-four-dimension-consent-framework 2026-06-24T18:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sponsors-urged-to-drop-qes-everywhere-default-in-global-trials-adopt-four-dimension-consent-framework 2026-06-24T18:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/france-confirms-first-ebola-case-outside-africa-in-drc-bundibugyo-outbreak-as-un-warns-of-unprecedented-spread 2026-06-24T18:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/france-confirms-first-ebola-case-outside-africa-in-drc-bundibugyo-outbreak-as-un-warns-of-unprecedented-spread 2026-06-24T18:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/danaher-s-masimo-acquisition-and-biotech-guidance-cut-a-tale-of-two-catalysts 2026-06-24T17:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danaher-s-masimo-acquisition-and-biotech-guidance-cut-a-tale-of-two-catalysts 2026-06-24T17:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/metabolon-delivers-landmark-metabolomics-dataset-from-7500-participants-to-genomics-england-s-100000-genomes-project 2026-06-24T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolon-delivers-landmark-metabolomics-dataset-from-7500-participants-to-genomics-england-s-100000-genomes-project 2026-06-24T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/deep-learning-identifies-novel-ecg-biomarker-for-sudden-cardiac-death-published-in-nature 2026-06-24T17:08:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deep-learning-identifies-novel-ecg-biomarker-for-sudden-cardiac-death-published-in-nature 2026-06-24T17:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-complete-response-letters-how-crls-reshape-biotech-valuations-and-drug-development-timelines 2026-06-24T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-complete-response-letters-how-crls-reshape-biotech-valuations-and-drug-development-timelines 2026-06-24T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/africa-launches-continental-biotech-database-to-streamline-regulatory-access-and-boost-agricultural-biotechnology 2026-06-24T17:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/africa-launches-continental-biotech-database-to-streamline-regulatory-access-and-boost-agricultural-biotechnology 2026-06-24T17:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-devices-detect-cytokine-release-syndrome-7-hours-earlier-in-car-t-recipients-pilot-study-shows 2026-06-24T17:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wearable-devices-detect-cytokine-release-syndrome-7-hours-earlier-in-car-t-recipients-pilot-study-shows 2026-06-24T17:08:05+00:00 hourly 0.9